pravastatin has been researched along with Arteriosclerosis, Coronary in 194 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 1 (0.52) | 18.7374 |
| 1990's | 44 (22.68) | 18.2507 |
| 2000's | 110 (56.70) | 29.6817 |
| 2010's | 39 (20.10) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Colquhoun, DM; Glozier, N; Kirby, AC; Marschner, SL; Nestel, PJ; O'Neil, A; Oldenburg, B; Simes, J; Stewart, RAH; Tonkin, AM; White, HD | 1 |
| Ahn, CM; Cheong, SS; Cho, DK; Cho, YH; Choi, D; Her, AY; Hong, MK; Im, E; Jang, Y; Kang, WC; Kim, BK; Kim, JS; Kim, YH; Ko, YG; Lee, K; Shin, DH; Suh, Y; Yoo, SY; Yun, KH | 1 |
| Butts, M; Spiro, J | 1 |
| Codoñer, MB; González-Santos, JM; Kassan, M; López-Rodríguez, J; Montero, MJ; Sevilla, MA; Sorlí, MJ | 1 |
| Hattori, H; Hirano, T; Ishihara, M; Iwasaki, T; Kawashiri, MA; Michishita, I; Nozue, T; Yamagishi, M | 1 |
| Fukui, K; Hibi, K; Kunishima, T; Michishita, I; Miyake, S; Morino, Y; Muramatsu, T; Nozato, T; Nozue, T; Onishi, Y; Sato, A; Takeyama, Y; Terashima, M; Tohyama, S; Umezawa, S; Yamamoto, S; Yamauchi, T | 4 |
| Alexopoulos, N; Arepalli, CD; Chen, Z; Hartlage, GR; Kim, S; Melek, BH; Raggi, P; Stillman, AE | 1 |
| Fukui, K; Hibi, K; Kunishima, T; Michishita, I; Morino, Y; Nozue, T; Onishi, Y; Sozu, T; Takeyama, Y; Terashima, M; Tohyama, S; Umezawa, S; Yamamoto, S; Yamauchi, T | 1 |
| Choi, H; Han, SH; Koh, KK; Lee, K; Lee, Y; Lim, S; Oh, PC; Quon, MJ; Sakuma, I; Shin, EK | 1 |
| Kang, S; Liu, XB; Liu, Y | 1 |
| Cheng, X; Cho, KH; Hong, SH; Jang, HH; Kim, JB; Kim, KS; Kim, W; Kim, WS; Lee, KH; Lee, SR; Min, BI; Woo, JS | 1 |
| Ikeda, T; Ikuta, S; Iwanaga, Y; Kobuke, K; Miyazaki, S; Ueno, M; Yamaji, K; Yamamoto, H; Yasuda, M | 1 |
| Uemura, S | 1 |
| Aktaş, SG; Atay, A; Çuhadar, S; Dursun, S; Köseoğlu, M | 1 |
| Aparicio, B; Bueno, MJ; Castaño, M; Centeno, JE; Díez, R; García, B; García-Criado, FJ; González-Santos, JM; López, J; Rodríguez, JM; Sagredo, V | 1 |
| Blankenberg, S; Colquhoun, DM; Funke-Kaiser, A; Hague, W; Hunt, D; Keech, AC; Kirby, A; Nestel, P; Simes, J; Stewart, R; Sullivan, DR; Thompson, PL; Tonkin, AM; West, M; White, HD; Zeller, T | 1 |
| Choi, D; Hong, MK; Jang, Y; Kim, BK; Kim, JH; Kim, JS; Ko, YG; Shin, DH | 1 |
| Colquhoun, DM; Glasziou, PP; Hague, WE; Hunt, D; Keech, AC; Kirby, A; Nestel, PJ; Pater, H; Simes, J; Stewart, RA; Sullivan, DR; Thompson, PL; Tonkin, AM; West, M; White, HD | 1 |
| Choi, D; Hong, MK; Jang, Y; Kim, BK; Ko, YG; Lee, JH; Shin, DH | 1 |
| Brener, SJ; Hu, T; Ivanc, TB | 1 |
| Divchev, D; Drexler, H; Grothusen, C; Koch, R; Luchtefeld, M; Onono, F; Schieffer, B; Thoenes, M | 1 |
| Abe, N; Fujiwara, T; Fukuda, I; Fukui, K; Hanada, H; Higuma, T; Kameda, K; Okumura, K; Osanai, T; Saito, S; Yokoyama, J | 1 |
| Bots, ML; Doevendans, PA; Grobbee, DE; Jukema, JW; Kastelein, JJ; Kuivenhoven, JA; Regieli, JJ; van der Graaf, Y; Zwinderman, AH | 1 |
| Itoh, T; Minami, Y; Nakamura, M; Satoh, M; Tabuchi, T; Takahashi, Y | 1 |
| Hibi, K; Kunishima, T; Michishita, I; Miyake, S; Morino, Y; Muramatsu, T; Nozue, T; Sato, A; Sozu, T; Takeyama, Y; Tohyama, S; Umezawa, S; Yamamoto, S; Yamauchi, T | 1 |
| Bolli, R; Dawn, B | 1 |
| Itoh, T; Maesawa, C; Minami, Y; Nakamura, M; Satoh, M; Tabuchi, T; Takahashi, Y | 1 |
| Anazawa, T; Furuya, S; Hirayama, A; Iida, K; Kawamata, H; Kumabe, N; Matsumoto, M; Nagao, K; Takahashi, H; Tani, S; Washio, T | 4 |
| Amano, A; Daida, H; Kajimoto, K; Kasai, T; Kubota, N; Kurata, T; Miyauchi, K | 1 |
| Aihara, K; Amano, A; Daida, H; Kajimoto, K; Kasai, T; Kojima, T; Kubota, N; Kurata, T; Miyauchi, K; Tamura, H; Yokoyama, K | 1 |
| Daida, H; Hata, M; Kaku, K; Kawamori, R; Kishimoto, J; Kurabayashi, M; Masuda, I; Nohara, R; Sakuma, I; Yamazaki, T; Yokoi, H; Yoshida, M | 1 |
| Fujioka, D; Hirano, M; Kawabata, K; Kitta, Y; Kobayashi, T; Kugiyama, K; Mishina, H; Nakamura, T; Obata, JE; Saito, Y; Sano, K; Watanabe, K; Watanabe, Y; Yano, T | 1 |
| Daitoku, K; Fukuda, I; Hanada, H; Higuma, T; Okumura, K; Osanai, T; Saito, S; Yokoyama, H | 1 |
| Alipour, A; Cabezas, MC; Defesche, JC; Elte, JW; Jukema, JW; Ribalta, J; Vallvé, JC; Zwinderman, AH | 1 |
| Anazawa, T; Furuya, S; Hirayama, A; Iida, K; Kawamata, H; Kobori, M; Kumabe, N; Matsumoto, M; Nagao, K; Takahashi, H; Tani, S; Washio, T | 1 |
| Braunwald, E; Pfeffer, MA; Ridker, PM; Sacks, FM | 1 |
| Nakamura, M; Satoh, M; Tabuchi, T; Takahashi, Y | 1 |
| Hirayama, A; Nagao, K; Tani, S | 1 |
| Hibi, K; Kunishima, T; Michishita, I; Miyake, S; Morino, Y; Muramatsu, T; Nozue, T; Sato, A; Sozu, T; Takeyama, Y; Terashima, M; Tohyama, S; Umezawa, S; Yamamoto, S; Yamauchi, T | 1 |
| Ahn, JH; Bliden, KP; Gho, EH; Gurbel, PA; Hwang, JY; Hwang, SJ; Jeong, YH; Kim, S; Kwak, CH; Kwon, TJ; Park, JR; Park, Y; Tantry, US | 1 |
| Fukui, K; Hibi, K; Kunishima, T; Michishita, I; Nozue, T; Onishi, Y; Terashima, M; Tohyama, S; Umezawa, S; Yamamoto, S | 1 |
| Kovalchik, SA | 1 |
| Daida, H; Kitagawa, Y; Teramoto, T | 1 |
| Fukui, K; Hibi, K; Kunishima, T; Michishita, I; Miyake, S; Morino, Y; Muramatsu, T; Nozato, T; Nozue, T; Onishi, Y; Sato, A; Takeyama, Y; Tohyama, S; Umezawa, S; Yamamoto, S; Yamauchi, T | 1 |
| Dirschinger, J; Holle, H; Hösl, K; Kastrati, A; Kastrati, D; Mehilli, J; Neumann, FJ; Pache, J; Schömig, A; Seyfarth, M | 1 |
| Liao, JK | 1 |
| Cobbe, S; Ford, I; Packard, CJ; Shepherd, J; Streja, L | 1 |
| Mehta, JL; Singh, BK | 1 |
| Anderson, JL; Zebrack, JS | 1 |
| Blauw, GJ; Bollen, EL; Buckley, BM; Cobbe, SM; Ford, I; Gaw, A; Hyland, M; Jukema, JW; Kamper, AM; Macfarlane, PW; Meinders, AE; Murphy, MB; Norrie, J; Packard, CJ; Perry, IJ; Shepherd, J; Stott, DJ; Sweeney, BJ; Twomey, C; Westendorp, RG | 1 |
| Ako, JY; Daida, H; Eto, M; Kurata, T; Mokuno, H; Nishide, T; Ouchi, Y; Saito, Y; Sato, H; Tango, T; Yamada, N; Yamaguchi, H | 1 |
| Bortolini, EB; Brüch, RS; Buffé, F; Mastalir, ET; Moriguchi, EH; Portal, VL; Rodrigues, R; Schio, S; Vieira, J | 1 |
| Kerensky, RA; Monroe, VS; Pepine, CJ; Rivera, E; Smith, KM | 1 |
| Bruschke, AV; Mulder, HJ; Schalij, MJ; van Geel, PP; van Gilst, WH; Zwinderman, AH | 1 |
| Agema, WR; Boekholdt, SM; Jukema, JW; Kastelein, JJ; Peters, RJ; Reitsma, PH; van der Wall, EE; Zwinderman, AH | 1 |
| Betz, W; Buntinx, F; Devroey, D; Kartounian, J; Vandevoorde, J | 1 |
| Andreassen, AK; Endresen, K; Geiran, O; Hognestad, A; Holm, T; Kjekshus, JK; Simonsen, S; Stokke, O; Wergeland, R | 1 |
| Awasthi, A; Guido, JJ; Kalaria, VG; Mackin, ML; Pearson, TA; Rains, A; Schwartz, RG; Shah, A; Williford, DJ | 1 |
| Aronow, WS | 1 |
| Arulchelvam, M; Baker, J; Beller, E; Best, J; Colquhoun, D; Hague, W; Hunt, D; Keech, A; Kirby, A; Simes, RJ; Tonkin, A | 1 |
| Furukawa, K; Ishikawa, K; Kanmatsuse, K; Kushiro, T; Matsumoto, M; Nagao, K; Nomoto, K; Tani, S; Watanabe, I | 1 |
| Origasa, H; Yokoyama, M | 1 |
| Mishra, TK; Routray, S | 1 |
| Fujiwara, M; Hasegawa, A; Horimoto, M; Igarashi, K; Inoue, H; Takenaka, T | 1 |
| Brown, WV; Moussa, M | 1 |
| Antonini-Canterin, F; Cervesato, E; Granata, G; Nicolosi, GL; Pavan, D; Piazza, R; Popescu, BA; Zuppiroli, A | 1 |
| Boekholdt, SM; de Maat, MP; Jukema, JW; Kastelein, JJ; Peters, RJ; Reitsma, PH; van Der Wall, EE; Zwinderman, AH | 1 |
| Einecke, D | 2 |
| de Grooth, GJ; Jukema, JW; Kastelein, JJ; Klerkx, AH; Kuivenhoven, JA; Zwinderman, AH | 1 |
| Brodie, B; Brown, BG; Cooper, CJ; Crowe, T; DeMaria, AN; Ganz, P; Grines, CL; Howard, G; Nissen, SE; Schoenhagen, P; Tuzcu, EM; Vogel, RA | 1 |
| Sacks, FM | 1 |
| Belder, R; de Grooth, GJ; Hu, B; Huang, SP; Jukema, JW; Kastelein, JJ; Kirchgessner, T; Klerkx, AH; Kuivenhoven, JA; Sacks, FM; Tsuchihashi, Z; Vishnupad, P; Zerba, KE; Zwinderman, AH | 1 |
| Fang, CH; Li, JJ | 1 |
| Agema, WR; de Maat, MP; Kastelein, JJ; Rabelink, TJ; van der Wall, EE; Wouter Jukema, J; Zwinderman, AH | 1 |
| Barter, P; Colquhoun, D; Glasziou, P; Hunt, D; Keech, A; Marschner, I; Simes, J; Tonkin, A; White, H | 1 |
| Kulbertus, H; Scheen, AJ | 1 |
| Salam, AM | 1 |
| Bilchick, KC; Blumenthal, RS; Henrikson, CA; Kasper, EK; Skojec, D | 1 |
| Awata, N; Hiraoka, H; Iida, M; Itoh, T; Kato, O; Kirino, M; Kobayashi, T; Nakagawa, T; Nakajima, H; Reiber, JH; Sato, S; Shibata, N; Takeda, Y; Toyama, YN; Yachiku, K | 1 |
| Cannon, CP; Ray, KK | 1 |
| Crowe, T; Ganz, P; Magorien, RD; Nissen, SE; O'Shaughnessy, C; Orazem, J; Sasiela, WJ; Schoenhagen, P; Tsai, J; Tuzcu, EM | 1 |
| Hofman, MK; Jukema, JW; Princen, HM; Zwinderman, AH | 1 |
| Farmer, JA | 1 |
| Judge, HM; Peters, G; Smith, SM; Storey, RF | 1 |
| Koizumi, J; Mabuchi, H; Miyamoto, S; Origasa, H; Shimizu, M | 1 |
| Marian, AJ | 1 |
| Riesen, WF | 1 |
| Daida, H; Endo, M; Furuse, A; Hosoda, S; Hosoda, Y; Makuuchi, H; Nakamura, H; Ohashi, Y; Watanabe, M; Yamaguchi, H; Yasui, H | 1 |
| Kastelein, JJ; van Leuven, SI | 1 |
| Beanlands, R; deKemp, RA; Duchesne, L; Higginson, L; Ling, MC; McPherson, R; Ruddy, TD; Ukkonen, H; Williams, KA | 1 |
| Albert, MA; Glynn, RJ; Ridker, PM; Wolfert, RL | 1 |
| Kawaguchi, A; Mitsudo, K; Nobuyoshi, M; Yamamoto, A; Yokoi, H | 1 |
| Gielen, S; Hambrecht, R | 1 |
| Allemann, Y; Eyer, S; Hess, OM; Kartal, N; Saner, H; Stengel, SM; Vetter, C | 1 |
| Cicero, AF; Gaddi, A | 1 |
| Austin, PC; Mamdani, MM | 1 |
| Gotto, AM | 2 |
| Nissen, SE | 1 |
| Fukui, T; Matsui, K; Nagata-Kobayashi, S; Shimbo, T | 1 |
| Fukushima, H; Hirai, T; Honda, O; Horibata, Y; Koga, H; Kugiyama, K; Ogawa, H; Sakamoto, T; Sugiyama, S; Watanabe, K; Yamashita, Y; Yoshimura, M | 1 |
| Crowe, T; Kapadia, S; Nicholls, SJ; Nissen, SE; Schoenhagen, P; Sipahi, I; Tuzcu, EM | 1 |
| Chen, MS; Crowe, T; Kapadia, S; Loyd, AB; Nicholls, SJ; Nissen, SE; Schoenhagen, P; Sipahi, I; Tuzcu, EM | 1 |
| Rosenson, RS | 1 |
| Apperson-Hansen, C; Churchill, T; Crowe, T; Lin, S; Loyd, A; Magyar, WA; Nicholls, SJ; Nissen, SE; Schoenhagen, P; Sipahi, I; Tuzcu, EM; Wang, C; Wolski, K | 1 |
| Magi, L; Morosini, P; Rafaiani, S; Settembri, P; Sforza, P | 1 |
| De Boer, A; De Knijff, P; Hallman, DM; Jukema, JW; Kastelein, JJ; Maitland-van der Zee, AH; Zwinderman, AH | 1 |
| Fiŝer, I; Kvas, E; Marschang, P; Patsch, JR; Ritsch, A; Sandhofer, A | 1 |
| Alberti, A; Bergamasco, L; Brscic, E; Celeste, A; De Bernardi, A; Formato, L; Fuster, V; Moretti, C; Pucci, A; Sheiban, I; Trevi, G | 1 |
| Ogawa, H; Sakamoto, K; Sakamoto, T | 1 |
| Fukushima, H; Funahashi, T; Horibata, Y; Koga, H; Kojima, S; Kugiyama, K; Maruyoshi, H; Ogawa, H; Otsuka, F; Sakamoto, T; Shimomura, I; Sugamura, K; Sugiyama, S; Watanabe, K | 1 |
| Mason, RP | 1 |
| Boukriche, Y; Dumas, C; Nangou, P; Oziol, E; Reny, JL; Sedighian, S; Simorre, B | 1 |
| Gutkowski, K; Lubas, W | 1 |
| Anazawa, T; Fuji, T; Hirayama, A; Kanmatsuse, K; Kawamata, H; Kushiro, T; Matsumoto, M; Nagao, K; Onikura, M; Sato, Y; Tachibana, E; Tani, S; Watanabe, I | 1 |
| Braunwald, E; Cannon, CP; Morrow, DA; Ray, KK; Rifai, N; Sabatine, MS; Shui, A | 1 |
| Matsuyama, Y; Ohashi, Y; Yoshida, M | 1 |
| Fujiwara, T; Fukuda, I; Fukui, K; Matsunaga, T; Minagawa, K; Okumura, K; Osanai, T; Saito, S | 1 |
| Kushiro, T; Mizuno, K; Nakamura, H; Nakaya, N; Ohashi, Y; Tajima, N; Teramoto, T; Uchiyama, S | 1 |
| Shaley, FM | 1 |
| Chen, JW; Chen, YH; Huang, SL; Leu, HB; Lin, CP; Lin, WT; Liu, TZ | 1 |
| Anazawa, T; Hirayama, A; Iida, K; Kawamata, H; Matsumoto, M; Nagao, K; Sato, Y; Tani, S | 1 |
| Farmer, JA; Jones, PH | 1 |
| Ackerstaff, RA; Bruschke, AV; de Groot, E; Jukema, JW; Lie, KI; Reiber, JH; van Boven, AJ; Zwinderman, AH | 1 |
| Byington, RP; Furberg, CD; McGovern, ME; Park, JS; Pitt, B | 1 |
| Ellis, SG; Mancini, GB; McGovern, ME; Park, JS; Pitt, B; Rosman, HS | 1 |
| Iwase, T; Nakanishi, S; Nishiyama, S; Seki, A | 1 |
| Gibson, CM; Pasternak, RC; Rosner, B; Sacks, FM; Stone, PH | 1 |
| Diament, J; Giannini, SD | 1 |
| Ellis, SG; Mancini, GB; McGovern, ME; Pitt, B; Rosman, HS | 1 |
| Bruschke, AV; Jukema, JW; Lie, KI; Reiber, JH; van Boven, AJ; Van der Laarse, A; Zwinderman, AH | 1 |
| Bruschke, AV; Byington, RP; Furberg, CD; Hoen, H; Jukema, JW; Mancini, GB; Pitt, B; Salonen, JT | 1 |
| Bal, ET; Bruschke, AV; Jukema, JW; Reiber, JH; van Boven, AJ; Zinderman, AH | 1 |
| Drown, DJ | 1 |
| Ashraf, T; Crouse, J; Davidson, M; Furberg, CD; Hay, JW; Pitt, B; Radican, L; Wittels, E | 1 |
| Daida, H; Lee, YJ; Miyano, H; Mokuno, H; Sakurai, H; Takaya, J; Yamaguchi, H; Yokoi, H | 1 |
| Bruin, T; Bruschke, AV; Gagné, E; Groenemeijer, B; Hayden, MR; Henneman, JA; Jansen, H; Jukema, JW; Kastelein, JJ; Molhoek, GP; Reiber, JH; van Boven, AJ; Zwinderman, AH | 1 |
| Rackley, CE | 1 |
| Pederson, JP; Weintraub, WS | 1 |
| Akimoto, N; Koyama, I; Ogawa, N; Omoto, R; Shibata, T; Shinozuka, N; Taguchi, Y; Watanabe, T | 1 |
| Mikuriya, Y; Nasu, M; Tamura, A | 1 |
| Shepherd, J | 1 |
| Boerwinkle, E; Bruin, T; Bruschke, AV; Gagné, E; Groenemeijer, BE; Hallman, MD; Hayden, MR; Jansen, H; Kastelein, JJ; Kuivenhoven, JA; Lie, KI; Reymer, PW | 1 |
| Akasaka, T; Hozumi, T; Morioka, S; Takagi, T; Yoshida, K; Yoshikawa, J | 1 |
| Aengevaeren, WR; Bruschke, AV; Jukema, JW; Uijen, GJ; van der Werf, T | 1 |
| Bruschke, AV; Cobbaert, C; Jukema, JW; Lindemans, J; Withagen, AJ; Zwinderman, AH | 1 |
| Bruschke, AV; de Knijff, P; Jukema, JW; Kastelein, JJ; Kuivenhoven, JA; Lie, KI; McPherson, R; Zwinderman, AH | 1 |
| Rosenthal, N; Schwartz, RS | 1 |
| Jukema, JW; Reiber, JH; van Boven, AJ; Zwinderman, AH | 1 |
| Herrington, DM; Libby, P; Sukhova, GK; Williams, JK | 1 |
| Kesäniemi, YA | 1 |
| Goldstein, MR | 1 |
| Dullaart, RP; van Tol, A | 1 |
| Ackerstaff, RG; Bom, N; Bruschke, AV; de Groot, E; Jukema, JW; Lie, KI; Montauban van Swijndregt, AD; van der Steen, AF; Zwinderman, AH | 1 |
| Bruschke, AV; Jukema, JW; van Boven, AJ; Van der Laarse, A; Zwinderman, AH | 1 |
| Mabuchi, H | 1 |
| Bräsen, JH; Harsch, M; Niendorf, A | 1 |
| Pritzker, LB | 1 |
| Beekman, M; Bruschke, AV; de Maat, MP; Henney, AM; Humphries, SE; Jukema, JW; Kastelein, JJ; Kluft, C; Moghaddam, PH; van Boven, AJ; Ye, S; Zwinderman, AH | 1 |
| Pedersen, TR | 1 |
| Aengevaeren, WR | 1 |
| Arntz, HR | 1 |
| Avellone, G; Bono, M; De Simone, R; Di Garbo, V; Di Raimondo, D; Raneli, G | 1 |
| Verdery, R | 1 |
| Brown, WV | 1 |
| Agrawal, R; Arntz, HR; Fischer, F; Schnitzer, L; Schultheiss, HP; Stern, R; Wunderlich, W | 1 |
| Rifai, N; Yu, H | 1 |
| Hayashi, K | 1 |
| Maeda, K; Minami, M; Yasunari, K; Yoshikawa, J | 1 |
| Fan, YM; Janatuinen, T; Knuuti, J; Laaksonen, R; Lehtimäki, T; Nuutila, P; Vesalainen, R | 1 |
| Egashira, K; Eshima, K; Hironaga, K; Hirooka, Y; Masumoto, A; Setoguchi, S; Takeshita, A | 1 |
| Adachi, M; Hirano, T; Katagiri, T; Koba, S; Sakai, K; Sakaue, T; Yoshino, G | 1 |
| Altamura, L; Chiariello, L; Crea, F; Gaspardone, A; Gioffrè, PA; Proietti, I; Tomai, F; Versaci, F | 1 |
| Gutzwiller, F; Muntwyler, J | 1 |
| Badimon, JJ; Carvalho, AC; de Paola, AV; Fonseca, FA; Ihara, SS; Izar, MC; Kasinski, N; Lopes, IL; Paiva, TB; Pinto, LE; Silva, EP; Tuffik, S | 1 |
| Giri, S; Moyna, NM; Thompson, PD; Waters, DD; Weber, KM; White, CM | 1 |
| Böhm, M; Hamm, CW; Heeschen, C; Laufs, U; Snapinn, S; White, HD | 1 |
| de Boer, A; Fishman, PA; Heckbert, SR; Klungel, OH; Leufkens, HG; Psaty, BM; Sullivan, SD; Veenstra, DL | 1 |
| Hayasaki, K; Kawaguchi, A; Minamino, R; Mitsudo, K; Nakashima, M; Nobuyoshi, M; Yamamoto, A | 1 |
| Freedman, DS; Otvos, JD; Rosenson, RS | 1 |
| Arai, H; Hara, S; Ishii, K; Kita, T; Kume, N; Nagano, Y; Otani, H; Ueda, Y; Yokode, M | 1 |
| Inoue, N; Itoh, H; Kishino, B; Koga, N; Nakashima, Y; Nishide, T; Okamura, K; Saito, Y; Tatami, R; Teramoto, T | 1 |
| Arai, M; Fukami, M; Ito, T; Kuroda, M; Shiomi, M; Tamura, A; Tsujita, Y; Watanabe, Y | 1 |
26 review(s) available for pravastatin and Arteriosclerosis, Coronary
| Article | Year |
|---|---|
Effects of aggressive statin therapy on patients with coronary saphenous vein bypass grafts: a systematic review and meta-analysis of randomized, controlled trials.
Topics: Adult; Aged; Atorvastatin; Cholesterol, LDL; Coronary Artery Bypass; Coronary Artery Disease; Female; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Male; Middle Aged; Myocardial Infarction; Pravastatin; Pyrroles; Randomized Controlled Trials as Topic; Registries; Saphenous Vein; Simvastatin; Treatment Outcome; Young Adult | 2013 |
Long-Term Effectiveness and Safety of Pravastatin in Patients With Coronary Heart Disease: Sixteen Years of Follow-Up of the LIPID Study.
Topics: Coronary Artery Disease; Double-Blind Method; Female; Follow-Up Studies; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Longitudinal Studies; Male; Multicenter Studies as Topic; Pravastatin; Randomized Controlled Trials as Topic; Survival Rate; Time Factors | 2016 |
Beyond lipid lowering: the role of statins in vascular protection.
Topics: Animals; Cardiovascular Diseases; Coronary Artery Disease; Endothelium, Vascular; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Neovascularization, Physiologic; Pravastatin; Randomized Controlled Trials as Topic; Simvastatin; Stroke | 2002 |
Management of dyslipidemia in the primary prevention of coronary heart disease.
Topics: Animals; Cholesterol, HDL; Clinical Trials as Topic; Coronary Artery Disease; Coronary Disease; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hyperlipidemias; Lovastatin; Practice Guidelines as Topic; Pravastatin; Risk Factors | 2002 |
Role of inflammation in cardiovascular disease: how to use C-reactive protein in clinical practice.
Topics: Age Factors; Anticholesteremic Agents; Arteriosclerosis; Biomarkers; C-Reactive Protein; Coronary Artery Disease; Humans; Inflammation; Pravastatin; Risk Factors; Sensitivity and Specificity | 2002 |
Pharmacologic plaque passivation for the reduction of recurrent cardiac events in acute coronary syndromes.
Topics: Abciximab; Acute Disease; Angina, Unstable; Antibodies, Monoclonal; C-Reactive Protein; Coronary Artery Disease; Coronary Thrombosis; Disease Progression; Endothelium, Vascular; Enoxaparin; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Immunoglobulin Fab Fragments; Macrophages; Myocardial Infarction; Platelet Aggregation Inhibitors; Platelet Glycoprotein GPIIb-IIIa Complex; Pravastatin; Randomized Controlled Trials as Topic; Secondary Prevention; Severity of Illness Index | 2003 |
Hypercholesterolemia. The evidence supports use of statins.
Topics: Aged; Cholesterol, HDL; Coronary Artery Disease; Female; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Male; Metabolic Syndrome; Pravastatin; Simvastatin | 2003 |
Perspectives from the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial--Lipid Lowering Trial and the Anglo-Scandinavian Cardiac Outcomes Trial--Lipid Lowering Arm.
Topics: Aged; Atorvastatin; Cholesterol, LDL; Coronary Artery Disease; Female; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypertension; Male; Middle Aged; Myocardial Infarction; Pravastatin; Pyrroles; Randomized Controlled Trials as Topic; Stroke; Treatment Outcome | 2003 |
Intensive lipid-lowering therapy in coronary artery disease: implications of the REVERSAL and PROVE-IT trials.
Topics: Anticholesteremic Agents; Atorvastatin; Cholesterol, LDL; Coronary Artery Disease; Heptanoic Acids; Humans; Pravastatin; Pyrroles; Randomized Controlled Trials as Topic; Treatment Outcome | 2004 |
Treatment of hyperlipidemia in cardiac transplant recipients.
Topics: Algorithms; Coronary Artery Disease; Endothelium, Vascular; Heart Transplantation; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hyperlipidemias; Hypolipidemic Agents; Immunosuppressive Agents; Pravastatin; Simvastatin | 2004 |
Intensive statin therapy in acute coronary syndromes: clinical benefits and vascular biology.
Topics: Acute Disease; Animals; Atorvastatin; Cholesterol; Clinical Trials as Topic; Coronary Artery Disease; Coronary Disease; Endothelial Cells; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Myocardial Infarction; Pravastatin; Pyrroles; Syndrome; T-Lymphocytes | 2004 |
Atorvastatin.
Topics: Anticholesteremic Agents; Atherosclerosis; Atorvastatin; Cardiovascular Diseases; Carotid Arteries; Cholesterol, LDL; Coronary Artery Disease; Drug Interactions; Endothelium, Vascular; Forecasting; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Leukocytes; Pravastatin; Proportional Hazards Models; Pyrroles; Randomized Controlled Trials as Topic | 2005 |
Review of primary and secondary prevention trials with lovastatin, pravastatin, and simvastatin.
Topics: Coronary Artery Disease; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Lovastatin; Pravastatin; Randomized Controlled Trials as Topic; Simvastatin | 2005 |
Effect of intensive lipid lowering on progression of coronary atherosclerosis: evidence for an early benefit from the Reversal of Atherosclerosis with Aggressive Lipid Lowering (REVERSAL) trial.
Topics: Atorvastatin; Coronary Artery Disease; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Pravastatin; Pyrroles; Randomized Controlled Trials as Topic; Treatment Outcome | 2005 |
Molecular basis of differences among statins and a comparison with antioxidant vitamins.
Topics: Antioxidants; Atorvastatin; Cholesterol, LDL; Coronary Artery Disease; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Pravastatin; Pyridines; Pyrroles; Vitamins | 2006 |
[C-reactive protein in cardiovascular diseases].
Topics: Algorithms; Biomarkers; C-Reactive Protein; Cardiovascular Diseases; Coronary Artery Disease; Humans; Inflammation; Inflammation Mediators; Pravastatin; Predictive Value of Tests; Risk Factors; Sensitivity and Specificity | 2006 |
Adjunctive interventions in myocardial infarction: the role of statin therapy.
Topics: Acute Coronary Syndrome; Anticholesteremic Agents; Atorvastatin; Coronary Artery Disease; Coronary Circulation; Coronary Occlusion; Dyslipidemias; Endothelium, Vascular; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Myocardial Infarction; Plasminogen Activator Inhibitor 1; Pravastatin; Pyrroles; Randomized Controlled Trials as Topic | 2008 |
Monotherapy with HMG-CoA reductase inhibitors and secondary prevention in coronary artery disease.
Topics: Carotid Artery Diseases; Clinical Trials as Topic; Coronary Artery Disease; Coronary Disease; Enzyme Inhibitors; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Lovastatin; Pravastatin; Simvastatin | 1996 |
Serum triglycerides and clinical benefit in lipid-lowering trials.
Topics: Anticholesteremic Agents; Bezafibrate; Cholesterol, LDL; Clinical Trials as Topic; Coronary Artery Disease; Coronary Disease; Estrogen Replacement Therapy; Female; Humans; Hypertriglyceridemia; Hypolipidemic Agents; Myocardial Infarction; Myocardial Ischemia; Postmenopause; Pravastatin; Risk Factors; Simvastatin; Triglycerides | 1998 |
[Hyperlipidemia and arteriosclerosis].
Topics: Anticholesteremic Agents; Coronary Artery Disease; Coronary Disease; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hyperlipidemias; Lovastatin; Pravastatin; Simvastatin | 1998 |
Do lipid lowering drugs reduce the risk of coronary heart disease?
Topics: Angiography; Anticholesteremic Agents; Clinical Trials as Topic; Clofibrate; Coronary Artery Disease; Coronary Disease; Europe; Humans; Hypolipidemic Agents; Lipoproteins, LDL; Pravastatin; Survival Rate | 1998 |
Statin trials and goals of cholesterol-lowering therapy after AMI.
Topics: Anticholesteremic Agents; Cholesterol, LDL; Coronary Artery Disease; Coronary Disease; Disease Progression; Europe; Humans; Myocardial Infarction; Myocardial Ischemia; Pravastatin; Prospective Studies; Randomized Controlled Trials as Topic; Scandinavian and Nordic Countries; Simvastatin; Survival Rate; United States | 1999 |
Beyond lipids - the role of the endothelium in coronary artery disease.
Topics: Animals; Anticholesteremic Agents; Coronary Artery Disease; Endothelium, Vascular; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Lipids; Pravastatin | 1999 |
Evidence for the benefit of early intervention with pravastatin for secondary prevention of cardiovascular events.
Topics: Angina Pectoris; Anticholesteremic Agents; Coronary Artery Disease; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Myocardial Infarction; Pravastatin; Recurrence | 1999 |
Cholesterol lowering in atherosclerosis.
Topics: Anticholesteremic Agents; Atorvastatin; Cholesterol, LDL; Coronary Artery Disease; Disease Progression; Heptanoic Acids; Humans; Pravastatin; Pyrroles; Simvastatin | 2000 |
[REGRESS [The Regression Growth Evaluation Statin Study]].
Topics: Adult; Aged; Anticholesteremic Agents; Coronary Angiography; Coronary Artery Disease; Double-Blind Method; Follow-Up Studies; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Lipids; Male; Middle Aged; Multicenter Studies as Topic; Pravastatin; Randomized Controlled Trials as Topic | 2001 |
92 trial(s) available for pravastatin and Arteriosclerosis, Coronary
| Article | Year |
|---|---|
High-intensity Statin Treatments in Clinically Stable Patients on Aspirin Monotherapy 12 Months After Drug-eluting Stent Implantation: A Randomized Study.
Topics: Aspirin; Atorvastatin; Coronary Artery Disease; Drug-Eluting Stents; Female; Graft Occlusion, Vascular; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Male; Middle Aged; Myocardial Infarction; Myocardial Revascularization; Platelet Aggregation Inhibitors; Pravastatin; Stroke; Treatment Outcome | 2018 |
Comparison of effects of pitavastatin versus pravastatin on serum proprotein convertase subtilisin/kexin type 9 levels in statin-naive patients with coronary artery disease.
Topics: Aged; Apoptosis; Biomarkers; Coronary Artery Disease; Dose-Response Relationship, Drug; Enzyme-Linked Immunosorbent Assay; Female; Follow-Up Studies; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Male; Pravastatin; Proprotein Convertase 9; Proprotein Convertases; Prospective Studies; Quinolines; Serine Endopeptidases; Severity of Illness Index; Treatment Outcome | 2013 |
Comparison of effects of serum n-3 to n-6 polyunsaturated fatty acid ratios on coronary atherosclerosis in patients treated with pitavastatin or pravastatin undergoing percutaneous coronary intervention.
Topics: Aged; Atherosclerosis; Biomarkers; Coronary Artery Disease; Dose-Response Relationship, Drug; Fatty Acids, Omega-3; Fatty Acids, Omega-6; Female; Follow-Up Studies; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Male; Percutaneous Coronary Intervention; Pravastatin; Prospective Studies; Quinolines; Severity of Illness Index; Treatment Outcome; Ultrasonography, Interventional | 2013 |
Effect of intensive versus moderate lipid-lowering therapy on epicardial adipose tissue in hyperlipidemic post-menopausal women: a substudy of the BELLES trial (Beyond Endorsed Lipid Lowering with EBT Scanning).
Topics: Adipose Tissue; Aged; Aged, 80 and over; Atherosclerosis; Atorvastatin; Coronary Artery Disease; Female; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hyperlipidemias; Middle Aged; Postmenopause; Pravastatin; Pyrroles; Vascular Calcification | 2013 |
C-reactive protein and future cardiovascular events in statin-treated patients with angina pectoris: the extended TRUTH study.
Topics: Aged; Angina Pectoris; C-Reactive Protein; Cardiovascular Diseases; Coronary Artery Disease; Female; Follow-Up Studies; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Ischemia; Japan; Male; Middle Aged; Myocardial Infarction; Plaque, Atherosclerotic; Pravastatin; Prospective Studies; Quinolines; Regression Analysis; Risk Factors; Treatment Outcome; Ultrasonography, Interventional | 2013 |
Combination pravastatin and valsartan treatment has additive beneficial effects to simultaneously improve both metabolic and cardiovascular phenotypes beyond that of monotherapy with either drug in patients with primary hypercholesterolemia.
Topics: Angiotensin II Type 1 Receptor Blockers; Body Mass Index; Brachial Artery; C-Reactive Protein; Coronary Artery Disease; Cross-Over Studies; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Drug Therapy, Combination; Endothelium, Vascular; Female; Glycated Hemoglobin; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Insulin Resistance; Lipids; Male; Middle Aged; Phenotype; Pravastatin; Tetrazoles; Treatment Outcome; Valine; Valsartan | 2013 |
Comparison of the effects of pitavastatin versus pravastatin on coronary artery plaque phenotype assessed by tissue characterization using serial virtual histology intravascular ultrasound.
Topics: Acute Coronary Syndrome; Aged; Coronary Artery Disease; Female; Humans; Male; Middle Aged; Necrosis; Phenotype; Plaque, Atherosclerotic; Pravastatin; Prospective Studies; Quinolines; Ultrasonography, Interventional | 2015 |
Difference in statin effects on neointimal coverage after implantation of drug-eluting stents.
Topics: Aged; Biomarkers; C-Reactive Protein; Coronary Artery Disease; Coronary Vessels; Drug-Eluting Stents; Female; Fluorobenzenes; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Japan; Lipids; Male; Middle Aged; Neointima; Percutaneous Coronary Intervention; Pravastatin; Prospective Studies; Pyrimidines; Rosuvastatin Calcium; Sulfonamides; Time Factors; Tomography, Optical Coherence; Treatment Outcome | 2014 |
Effect of preoperative oral pravastatin reload in systemic inflammatory response and myocardial damage after coronary artery bypass grafting. A pilot double-blind placebo-controlled study.
Topics: Administration, Oral; Aged; Anti-Inflammatory Agents; Biomarkers; Cardiopulmonary Bypass; Coronary Artery Bypass; Coronary Artery Disease; Creatine Kinase; Double-Blind Method; Drug Administration Schedule; Dyslipidemias; Female; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Male; Middle Aged; Nitric Oxide; Nitric Oxide Synthase Type II; Pilot Projects; Pravastatin; Preoperative Care; Risk Factors; Spain; Systemic Inflammatory Response Syndrome; Time Factors; Treatment Outcome | 2015 |
Biomarkers in stable coronary heart disease, their modulation and cardiovascular risk: The LIPID biomarker study.
Topics: 1-Alkyl-2-acetylglycerophosphocholine Esterase; Adrenomedullin; Adult; Aged; Biomarkers; C-Reactive Protein; Coronary Artery Disease; Cystatin C; Female; Fibrin Fibrinogen Degradation Products; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Male; Middle Aged; Natriuretic Peptide, Brain; Peptide Fragments; Pravastatin; Predictive Value of Tests; Prognosis; Risk Factors; Troponin I; Troponin T | 2015 |
Effect of High-Dose Statin Therapy on Drug-Eluting Stent Strut Coverage.
Topics: Aged; Atorvastatin; Coronary Angiography; Coronary Artery Disease; Coronary Vessels; Drug-Eluting Stents; Female; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Male; Middle Aged; Percutaneous Coronary Intervention; Pravastatin; Prospective Studies; Prosthesis Design; Republic of Korea; Time Factors; Tomography, Optical Coherence; Treatment Outcome; Vascular Remodeling; Wound Healing | 2015 |
Early Effects of Intensive Lipid-Lowering Treatment on Plaque Characteristics Assessed by Virtual Histology Intravascular Ultrasound.
Topics: Aged; Cholesterol, LDL; Coronary Artery Disease; Drug Administration Schedule; Ezetimibe, Simvastatin Drug Combination; Female; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Male; Middle Aged; Plaque, Atherosclerotic; Pravastatin; Prospective Studies; Time Factors; Treatment Outcome; Ultrasonography, Interventional | 2016 |
Impact of a combined treatment of angiotensin II type 1 receptor blockade and 3-hydroxy-3-methyl-glutaryl-CoA-reductase inhibition on secretory phospholipase A2-type IIA and low density lipoprotein oxidation in patients with coronary artery disease.
Topics: Adult; Aged; Analysis of Variance; Angiotensin II Type 1 Receptor Blockers; Biphenyl Compounds; C-Reactive Protein; Coronary Artery Disease; Dose-Response Relationship, Drug; Drug Therapy, Combination; Female; Group II Phospholipases A2; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Irbesartan; Lipoproteins, LDL; Male; Middle Aged; Pravastatin; Tetrazoles; Treatment Outcome | 2008 |
Effect of intensive lipid-lowering therapy on telomere erosion in endothelial progenitor cells obtained from patients with coronary artery disease.
Topics: Anticholesteremic Agents; Atorvastatin; Cell Count; Cells, Cultured; Cholesterol; Coronary Artery Disease; Endothelial Cells; Female; Heptanoic Acids; Humans; Male; Middle Aged; Pravastatin; Prospective Studies; Pyrroles; Single-Blind Method; Stem Cells; Telomere | 2009 |
Treatment with statin on atheroma regression evaluated by intravascular ultrasound with Virtual Histology (TRUTH Study): rationale and design.
Topics: Atherosclerosis; Coronary Artery Disease; Coronary Vessels; Endpoint Determination; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Japan; Pravastatin; Prospective Studies; Quinolines; Ultrasonography, Interventional; User-Computer Interface | 2009 |
Effect of atorvastatin on microRNA 221 / 222 expression in endothelial progenitor cells obtained from patients with coronary artery disease.
Topics: Aged; Anticholesteremic Agents; Atorvastatin; Coronary Artery Disease; Endothelial Cells; Female; Heptanoic Acids; Humans; Male; MicroRNAs; Middle Aged; Pravastatin; Prospective Studies; Pyrroles; Reverse Transcriptase Polymerase Chain Reaction; Single-Blind Method; Statistics as Topic; Stem Cells | 2009 |
Association of body mass index with coronary plaque regression: 6-month prospective study.
Topics: Aged; Body Mass Index; Cholesterol; Cholesterol, HDL; Coronary Artery Disease; Female; Humans; Leukocyte Count; Male; Middle Aged; Obesity; Pravastatin; Prospective Studies; Treatment Outcome; Ultrasonography | 2009 |
Association of leukocyte subtype counts with coronary atherosclerotic regression following pravastatin treatment.
Topics: Aged; Cholesterol, HDL; Coronary Artery Disease; Female; Follow-Up Studies; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Leukocyte Count; Male; Middle Aged; Monocytes; Pravastatin; Predictive Value of Tests; Prospective Studies; Remission Induction; Treatment Outcome; Ultrasonography, Interventional | 2009 |
Relation of change in apolipoprotein B/apolipoprotein A-I ratio to coronary plaque regression after Pravastatin treatment in patients with coronary artery disease.
Topics: Aged; Apolipoprotein A-I; Apolipoproteins B; Coronary Artery Disease; Female; Follow-Up Studies; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Male; Middle Aged; Pravastatin; Prospective Studies; Treatment Outcome; Ultrasonography, Interventional | 2010 |
Can intensive lipid-lowering therapy with statins ameliorate atherosclerosis in Japanese patients? Rationale and design of the JART study.
Topics: Adult; Anticholesteremic Agents; Cholesterol, LDL; Coronary Artery Disease; Female; Fluorobenzenes; Humans; Japan; Male; Pravastatin; Prospective Studies; Pyrimidines; Rosuvastatin Calcium; Sulfonamides; Treatment Outcome; Tunica Intima; Tunica Media; Young Adult | 2010 |
Coronary plaque regression and lifestyle modification in patients treated with pravastatin. - Assessment mainly by daily aerobic exercise and an increase in the serum level of high-density lipoprotein cholesterol -.
Topics: Aged; Anticholesteremic Agents; Cholesterol, HDL; Coronary Artery Disease; Coronary Vessels; Exercise; Female; Humans; Life Style; Male; Middle Aged; Pravastatin; Prospective Studies; Ultrasonography | 2010 |
Comparative study of bezafibrate and pravastatin in patients with coronary artery disease and high levels of remnant lipoprotein.
Topics: Aged; Anticholesteremic Agents; Bezafibrate; Cardiovascular Diseases; Cholesterol; Coronary Artery Disease; Female; Follow-Up Studies; Humans; Hypolipidemic Agents; Lipids; Lipoproteins; Male; Middle Aged; Pravastatin; Triglycerides | 2010 |
Effects of pravastatin and rosuvastatin on the generation of adiponectin in the visceral adipose tissue in patients with coronary artery disease.
Topics: Adiponectin; Aged; Cholesterol, LDL; Coronary Artery Disease; Female; Fluorobenzenes; Heart Valve Diseases; Humans; Interleukin-6; Intra-Abdominal Fat; Male; Middle Aged; Oxidative Stress; Pravastatin; Protein Carbonylation; Pyrimidines; Rosuvastatin Calcium; Subcutaneous Fat; Sulfonamides; Tumor Necrosis Factor-alpha | 2011 |
Prospective, randomized, single-blind comparison of effects of 6 months' treatment with atorvastatin versus pravastatin on leptin and angiogenic factors in patients with coronary artery disease.
Topics: Aged; Analysis of Variance; Angiogenic Proteins; Angiopoietin-2; Atorvastatin; Biomarkers; Coronary Artery Disease; Down-Regulation; Female; Hepatocyte Growth Factor; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Japan; Leptin; Lipids; Male; Middle Aged; Pravastatin; Prospective Studies; Pyrroles; Single-Blind Method; Time Factors; Treatment Outcome; Vascular Endothelial Growth Factor A | 2012 |
Statin treatment for coronary artery plaque composition based on intravascular ultrasound radiofrequency data analysis.
Topics: Aged; Coronary Artery Disease; Coronary Vessels; Dose-Response Relationship, Drug; Female; Follow-Up Studies; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Male; Plaque, Atherosclerotic; Pravastatin; Prospective Studies; Quinolines; Treatment Outcome; Ultrasonography, Interventional | 2012 |
Accelerated platelet inhibition by switching from atorvastatin to a non-CYP3A4-metabolized statin in patients with high platelet reactivity (ACCEL-STATIN) study.
Topics: Adenosine Diphosphate; Aspirin; Atorvastatin; Calcium Channel Blockers; Clopidogrel; Coronary Artery Disease; Cytochrome P-450 CYP3A; Drug Substitution; Drug Therapy, Combination; Female; Fluorobenzenes; Genotype; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Male; Middle Aged; Percutaneous Coronary Intervention; Platelet Aggregation; Platelet Aggregation Inhibitors; Pravastatin; Prospective Studies; Pyrimidines; Pyrroles; Rosuvastatin Calcium; Sulfonamides; Ticlopidine | 2012 |
Impacts of estimated glomerular filtration rate on coronary atherosclerosis and plaque composition before and during statin therapy in patients with normal to mild renal dysfunction: subanalysis of the TRUTH study.
Topics: Aged; Biomarkers; Coronary Artery Disease; Coronary Vessels; Dyslipidemias; Female; Fibrosis; Glomerular Filtration Rate; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Japan; Kidney; Kidney Diseases; Lipids; Male; Middle Aged; Multivariate Analysis; Percutaneous Coronary Intervention; Plaque, Atherosclerotic; Pravastatin; Prospective Studies; Quinolines; Risk Assessment; Risk Factors; Severity of Illness Index; Time Factors; Treatment Outcome; Ultrasonography, Interventional | 2012 |
Effects of serum n-3 to n-6 polyunsaturated fatty acids ratios on coronary atherosclerosis in statin-treated patients with coronary artery disease.
Topics: Aged; Biomarkers; Chromatography, Gas; Coronary Artery Disease; Coronary Vessels; Disease Progression; Fatty Acids, Omega-3; Fatty Acids, Omega-6; Female; Follow-Up Studies; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Male; Pravastatin; Prospective Studies; Quinolines; Treatment Outcome; Ultrasonography, Interventional | 2013 |
Effects of statins on serum n-3 to n-6 polyunsaturated fatty acid ratios in patients with coronary artery disease.
Topics: Aged; alpha-Linolenic Acid; Arachidonic Acid; Cholesterol, LDL; Coronary Artery Disease; Docosahexaenoic Acids; Eicosapentaenoic Acid; Fatty Acids, Omega-3; Fatty Acids, Omega-6; Female; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Japan; Longitudinal Studies; Male; Middle Aged; Pravastatin; Prospective Studies; Quinolines | 2013 |
Comparison of change in coronary atherosclerosis in patients with stable versus unstable angina pectoris receiving statin therapy (from the Treatment With Statin on Atheroma Regression Evaluated by Intravascular Ultrasound With Virtual Histology [TRUTH] s
Topics: Aged; Angina, Stable; Angina, Unstable; Biomarkers; Coronary Artery Disease; Female; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Japan; Lipids; Male; Plaque, Atherosclerotic; Pravastatin; Quinolines; Regression Analysis; Treatment Outcome; Ultrasonography, Interventional | 2013 |
Statin treatment following coronary artery stenting and one-year survival.
Topics: Coronary Artery Disease; Female; Humans; Male; Middle Aged; Pravastatin; Simvastatin; Stents; Survival Rate | 2002 |
Pravastatin in elderly individuals at risk of vascular disease (PROSPER): a randomised controlled trial.
Topics: Aged; Aged, 80 and over; Anticholesteremic Agents; Cholesterol, LDL; Coronary Artery Disease; Endpoint Determination; Female; Humans; Male; Pravastatin; Risk Factors | 2002 |
Preventing angiographic progression of coronary atherosclerosis with pravastatin.
Topics: Coronary Angiography; Coronary Artery Disease; Coronary Vessels; Disease Progression; Endpoint Determination; Female; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Lipids; Male; Middle Aged; Pravastatin; Prospective Studies; Regression Analysis; Risk Factors; Treatment Outcome | 2003 |
Comparison of the effect of two HMG CoA reductase inhibitors on LDL susceptibility to oxidation.
Topics: Adult; Aged; Antioxidants; Coronary Artery Disease; Double-Blind Method; Fatty Acids, Monounsaturated; Female; Fluvastatin; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Indoles; Lipids; Lipoproteins, LDL; Male; Middle Aged; Oxidation-Reduction; Pravastatin | 2003 |
DD ACE gene polymorphism is associated with increased coronary artery endothelial dysfunction: the PREFACE trial.
Topics: Coronary Artery Disease; Female; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Male; Peptidyl-Dipeptidase A; Polymorphism, Genetic; Pravastatin | 2003 |
Variants of toll-like receptor 4 modify the efficacy of statin therapy and the risk of cardiovascular events.
Topics: Amino Acid Substitution; Cohort Studies; Coronary Artery Disease; Disease Progression; Disease-Free Survival; Drosophila Proteins; Gene Frequency; Genetic Carrier Screening; Genetic Predisposition to Disease; Genotype; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Incidence; Male; Membrane Glycoproteins; Multicenter Studies as Topic; Polymorphism, Genetic; Pravastatin; Prospective Studies; Randomized Controlled Trials as Topic; Receptors, Cell Surface; Risk Assessment; Toll-Like Receptor 4; Toll-Like Receptors; Treatment Outcome | 2003 |
Plasma C-reactive protein as a marker of cardiac allograft vasculopathy in heart transplant recipients.
Topics: Adult; Aged; Anticholesteremic Agents; Biomarkers; C-Reactive Protein; Coronary Angiography; Coronary Artery Disease; Cross-Over Studies; Female; Heart Transplantation; Humans; Male; Middle Aged; Pravastatin; Predictive Value of Tests; Prospective Studies; Transplantation, Homologous | 2003 |
Secondary prevention of cardiovascular events with long-term pravastatin in patients with diabetes or impaired fasting glucose: results from the LIPID trial.
Topics: Adult; Aged; Angina, Unstable; Anticholesteremic Agents; Blood Glucose; Cardiovascular Diseases; Coronary Artery Disease; Coronary Restenosis; Diabetes Mellitus, Type 2; Fasting; Female; Follow-Up Studies; Glucose Intolerance; Humans; Hyperlipidemias; Male; Middle Aged; Myocardial Infarction; Pravastatin; Risk Factors; Stroke; Treatment Outcome | 2003 |
Effects of eicosapentaenoic acid on cardiovascular events in Japanese patients with hypercholesterolemia: rationale, design, and baseline characteristics of the Japan EPA Lipid Intervention Study (JELIS).
Topics: Adult; Aged; Angina, Unstable; Anticholesteremic Agents; Chemotherapy, Adjuvant; Coronary Artery Disease; Death, Sudden, Cardiac; Eicosapentaenoic Acid; Fatty Acids, Unsaturated; Female; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Japan; Male; Middle Aged; Myocardial Infarction; Pravastatin; Prospective Studies; Simvastatin | 2003 |
Long-term administration of pravastatin reduces serum lipoprotein(a) levels.
Topics: Aged; Cholesterol, LDL; Coronary Artery Disease; Drug Administration Schedule; Female; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hyperlipoproteinemias; Lipoprotein(a); Male; Middle Aged; Pravastatin | 2003 |
Interaction between a genetic variant of the platelet fibrinogen receptor and fibrinogen levels in determining the risk of cardiovascular events.
Topics: Coronary Artery Disease; Disease-Free Survival; Fibrinogen; Genotype; Humans; Integrin beta3; Male; Middle Aged; Platelet Aggregation; Platelet Glycoprotein GPIIb-IIIa Complex; Polymorphism, Genetic; Pravastatin; Proportional Hazards Models; Radiography; Receptors, Fibrinogen; Risk Assessment | 2004 |
Cholesteryl ester transfer protein concentration is associated with progression of atherosclerosis and response to pravastatin in men with coronary artery disease (REGRESS).
Topics: Carrier Proteins; Cholesterol; Cholesterol Ester Transfer Proteins; Cholesterol, HDL; Cholesterol, LDL; Coronary Angiography; Coronary Artery Disease; Double-Blind Method; Genotype; Glycoproteins; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Male; Middle Aged; Polymorphism, Genetic; Pravastatin; Triglycerides | 2004 |
Effect of intensive compared with moderate lipid-lowering therapy on progression of coronary atherosclerosis: a randomized controlled trial.
Topics: Anticholesteremic Agents; Atorvastatin; C-Reactive Protein; Cholesterol, HDL; Cholesterol, LDL; Coronary Artery Disease; Coronary Vessels; Disease Progression; Double-Blind Method; Female; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Liver Function Tests; Male; Middle Aged; Observer Variation; Pravastatin; Pyrroles; Ultrasonography, Interventional | 2004 |
Pharmacogenetics of the CD14 endotoxin receptor polymorphism and progression of coronary atherosclerosis.
Topics: Coronary Artery Disease; Disease Progression; Drug Resistance; Genotype; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Lipopolysaccharide Receptors; Middle Aged; Pharmacogenetics; Polymorphism, Single Nucleotide; Pravastatin; Promoter Regions, Genetic; Receptors, Immunologic | 2004 |
Effects of pravastatin on coronary events in 2073 patients with low levels of both low-density lipoprotein cholesterol and high-density lipoprotein cholesterol: results from the LIPID study.
Topics: Adult; Aged; Anticholesteremic Agents; Cholesterol, HDL; Cholesterol, LDL; Coronary Artery Disease; Female; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Male; Middle Aged; Pravastatin; Risk Factors; Treatment Outcome | 2004 |
[Clinical study of the month. REVERAL and PROVE-IT: confirmation of the concept " the lower, the better" for cholesterol therapy in patients with coronary heart disease].
Topics: Anticholesteremic Agents; Atorvastatin; Coronary Artery Disease; Coronary Disease; Dose-Response Relationship, Drug; Heptanoic Acids; Humans; Hypercholesterolemia; Pravastatin; Pyrroles; Randomized Controlled Trials as Topic | 2004 |
Randomized, controlled trial of secondary prevention of coronary sclerosis in normocholesterolemic patients using pravastatin: final 5-year angiographic follow-up of the Prevention of Coronary Sclerosis (PCS) study.
Topics: Adult; Aged; Cholesterol; Coronary Angiography; Coronary Artery Disease; Female; Follow-Up Studies; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Male; Middle Aged; Pravastatin; Reference Values; Time Factors | 2004 |
Statin therapy, LDL cholesterol, C-reactive protein, and coronary artery disease.
Topics: Anticholesteremic Agents; Atorvastatin; Biomarkers; C-Reactive Protein; Cholesterol, LDL; Coronary Artery Disease; Coronary Vessels; Disease Progression; Female; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Lipids; Male; Middle Aged; Myocardial Infarction; Pravastatin; Pyrroles; Regression Analysis; Risk Factors; Secondary Prevention; Ultrasonography, Interventional | 2005 |
Genetic variation in the rate-limiting enzyme in cholesterol catabolism (cholesterol 7alpha-hydroxylase) influences the progression of atherosclerosis and risk of new clinical events.
Topics: Analysis of Variance; Chi-Square Distribution; Cholesterol; Cholesterol 7-alpha-Hydroxylase; Coronary Artery Disease; Double-Blind Method; Gene Frequency; Genetic Predisposition to Disease; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Lipids; Male; Middle Aged; Polymorphism, Genetic; Pravastatin; Promoter Regions, Genetic; Risk Assessment; Triglycerides | 2005 |
Effect of pravastatin on progression of coronary atherosclerosis in patients after coronary artery bypass surgery.
Topics: Aged; Coronary Artery Bypass; Coronary Artery Disease; Disease Progression; Female; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Male; Middle Aged; Pravastatin | 2005 |
Early effects of statin therapy on endothelial function and microvascular reactivity in patients with coronary artery disease.
Topics: Aged; Coronary Artery Disease; Coronary Circulation; Endothelium, Vascular; Female; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Male; Microcirculation; Middle Aged; Positron-Emission Tomography; Pravastatin; Simvastatin; Time Factors; Ultrasonography | 2005 |
The effect of statin therapy on lipoprotein associated phospholipase A2 levels.
Topics: 1-Alkyl-2-acetylglycerophosphocholine Esterase; Adult; Aged; Anticholesteremic Agents; Biomarkers; Coronary Artery Disease; Female; Humans; Hypercholesterolemia; Male; Middle Aged; Phospholipases A; Phospholipases A2; Pravastatin; Regression Analysis; Risk Factors | 2005 |
Three-year follow-up results of angiographic intervention trial using an HMG-CoA reductase inhibitor to evaluate retardation of obstructive multiple atheroma (ATHEROMA) study.
Topics: Cholesterol, LDL; Coronary Artery Disease; Follow-Up Studies; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hyperlipidemias; Pravastatin | 2005 |
Effect of mild endurance exercise training and pravastatin on peripheral vasodilatation of forearm resistance vessels in patients with coronary artery disease.
Topics: Adult; Aged; Anticholesteremic Agents; Biomarkers; Coronary Artery Disease; Coronary Circulation; Endothelium, Vascular; Exercise; Exercise Test; Exercise Tolerance; Follow-Up Studies; Forearm; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Male; Middle Aged; Oxygen Consumption; Physical Endurance; Pravastatin; Regional Blood Flow; Treatment Outcome; Vascular Resistance; Vasodilation | 2005 |
Stabilization of carotid atheroma assessed by quantitative ultrasound analysis in nonhypercholesterolemic patients with coronary artery disease.
Topics: Atherosclerosis; C-Reactive Protein; Carotid Artery Diseases; Cholesterol, HDL; Cholesterol, LDL; Coronary Artery Disease; Female; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Magnetic Resonance Imaging; Male; Pravastatin; Prospective Studies; Triglycerides; Ultrasonography, Interventional | 2005 |
Paradoxical increase in lumen size during progression of coronary atherosclerosis: observations from the REVERSAL trial.
Topics: Adult; Aged; Anticholesteremic Agents; Atorvastatin; Coronary Angiography; Coronary Artery Disease; Disease Progression; Female; Follow-Up Studies; Heptanoic Acids; Humans; Male; Middle Aged; Pravastatin; Pyrroles; Severity of Illness Index; Treatment Outcome; Ultrasonography, Interventional | 2006 |
Determinants of arterial wall remodeling during lipid-lowering therapy: serial intravascular ultrasound observations from the Reversal of Atherosclerosis with Aggressive Lipid Lowering Therapy (REVERSAL) trial.
Topics: Adaptation, Physiological; Adult; Aged; Atorvastatin; C-Reactive Protein; Cardiac Catheterization; Cholesterol; Cholesterol, HDL; Cholesterol, LDL; Coronary Angiography; Coronary Artery Disease; Coronary Vessels; Female; Follow-Up Studies; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hyperlipidemias; Male; Middle Aged; Models, Cardiovascular; Pravastatin; Prospective Studies; Pyrroles; Risk Factors; Single-Blind Method; Triglycerides; Ultrasonography, Interventional; Vasculitis | 2006 |
Apolipoprotein-E polymorphism and response to pravastatin in men with coronary artery disease (REGRESS).
Topics: Aged; Anticholesteremic Agents; Apolipoprotein E2; Apolipoprotein E3; Apolipoprotein E4; Apolipoproteins E; Cholesterol; Cholesterol, HDL; Cholesterol, LDL; Coronary Artery Disease; Genetic Carrier Screening; Genetic Predisposition to Disease; Genotype; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Male; Middle Aged; Polymorphism, Genetic; Pravastatin; Regression Analysis; Statistics as Topic; Treatment Outcome; Triglycerides | 2006 |
In vivo coronary plaque histology in patients with stable and acute coronary syndromes: relationships with hyperlipidemic status and statin treatment.
Topics: Acute Disease; Aged; Angina, Unstable; Antigens, CD; Antigens, Differentiation, Myelomonocytic; Atherectomy, Coronary; Atorvastatin; Coronary Artery Disease; Coronary Vessels; Female; Glycophorins; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hyperlipidemias; Immunohistochemistry; Male; Middle Aged; Pravastatin; Pyrroles | 2007 |
Pravastatin improved glucose metabolism associated with increasing plasma adiponectin in patients with impaired glucose tolerance and coronary artery disease.
Topics: Adiponectin; Aged; Blood Glucose; Coronary Artery Disease; Female; Glucose Tolerance Test; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hyperglycemia; Male; Middle Aged; Postprandial Period; Pravastatin | 2007 |
Long-term prognostic value of neopterin: a novel marker of monocyte activation in patients with acute coronary syndrome.
Topics: Acute Disease; Anti-Infective Agents; Anticholesteremic Agents; Atorvastatin; Biomarkers; Coronary Artery Disease; Fluoroquinolones; Gatifloxacin; Heptanoic Acids; Humans; Monocytes; Neopterin; Pravastatin; Prognosis; Pyrroles; Risk Factors; Secondary Prevention; Survival Analysis | 2007 |
Estimation of treatment effect adjusting for dependent censoring using the IPCW method: an application to a large primary prevention study for coronary events (MEGA study).
Topics: Acyl Coenzyme A; Computer Simulation; Coronary Artery Disease; Data Interpretation, Statistical; Female; Humans; Incidence; Male; Middle Aged; Pravastatin; Primary Prevention; Probability; Prognosis; Proportional Hazards Models | 2007 |
Increased adiponectin synthesis in the visceral adipose tissue in men with coronary artery disease treated with pravastatin: a role of the attenuation of oxidative stress.
Topics: Adiponectin; Aged; Cholesterol; Coronary Artery Bypass; Coronary Artery Disease; Gene Expression Regulation; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Interleukin-6; Intra-Abdominal Fat; Male; Middle Aged; Oxidative Stress; Pravastatin; Tumor Necrosis Factor-alpha | 2008 |
Usefulness of pravastatin in primary prevention of cardiovascular events in women: analysis of the Management of Elevated Cholesterol in the Primary Prevention Group of Adult Japanese (MEGA study).
Topics: Adult; Age Factors; Aged; Cardiovascular Diseases; Cerebral Infarction; Coronary Artery Disease; Diet Therapy; Disease Management; Female; Humans; Hypercholesterolemia; Incidence; Japan; Lipids; Male; Middle Aged; Pravastatin; Sex Factors | 2008 |
Association of circulating leukocyte count with coronary atherosclerosis regression after pravastatin treatment.
Topics: Aged; Anticholesteremic Agents; Cholesterol; Coronary Artery Disease; Female; Humans; Leukocyte Count; Male; Middle Aged; Multivariate Analysis; Pravastatin; Prospective Studies; Regression Analysis; Treatment Outcome | 2008 |
Effect of pravastatin on progression and regression of coronary atherosclerosis and vessel wall changes in carotid and femoral arteries: a report from the Regression Growth Evaluation Statin Study.
Topics: Analysis of Variance; Anticholesteremic Agents; Carotid Arteries; Coronary Angiography; Coronary Artery Disease; Disease-Free Survival; Double-Blind Method; Enzyme Inhibitors; Femoral Artery; Follow-Up Studies; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Lipids; Male; Middle Aged; Netherlands; Pravastatin; Regression Analysis; Ultrasonography | 1995 |
Reduction in coronary events during treatment with pravastatin. PLAC I and PLAC II Investigators. Pravastatin Limitation of Atherosclerosis in the Coronary Arteries.
Topics: Aged; Anticholesteremic Agents; Arteriosclerosis; Carotid Artery Diseases; Coronary Artery Disease; Coronary Disease; Enzyme Inhibitors; Female; Follow-Up Studies; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Incidence; Male; Middle Aged; Myocardial Infarction; Pravastatin | 1995 |
Pravastatin limitation of atherosclerosis in the coronary arteries (PLAC I): reduction in atherosclerosis progression and clinical events. PLAC I investigation.
Topics: Aged; Anticholesteremic Agents; Cholesterol, LDL; Coronary Angiography; Coronary Artery Disease; Female; Humans; Male; Middle Aged; Myocardial Infarction; Pravastatin; Treatment Outcome | 1995 |
Effect on coronary atherosclerosis of decrease in plasma cholesterol concentrations in normocholesterolaemic patients. Harvard Atherosclerosis Reversibility Project (HARP) Group.
Topics: Anticholesteremic Agents; Cardiac Catheterization; Cholesterol; Cholesterol, HDL; Cholesterol, LDL; Cholestyramine Resin; Coronary Angiography; Coronary Artery Disease; Female; Follow-Up Studies; Gemfibrozil; Humans; Lipids; Male; Middle Aged; Niacin; Pravastatin; Treatment Outcome | 1994 |
[Pravastatin in patients with cardiac risk factors. Effects of pravastatin in patients with total serum cholesterol concentrations of 200 to 300 mg/dl (5.2 to 7.8 mmol/l) and two additional atherosclerosis risk factors. Pravastatin Multinational Study Gro
Topics: Adult; Aged; Aged, 80 and over; Cholesterol; Coronary Artery Disease; Double-Blind Method; Female; Humans; Hypercholesterolemia; Lipids; Long-Term Care; Male; Middle Aged; Pravastatin; Risk Factors | 1994 |
[Pravastatin: efficacy and safety in elderly patients with primary hypercholesterolemia. Open multicenter study].
Topics: Aged; Cholesterol; Coronary Artery Disease; Female; Humans; Hypercholesterolemia; Lipids; Lipoproteins; Male; Pravastatin | 1993 |
Design and recruitment in the United States of a multicenter quantitative angiographic trial of pravastatin to limit atherosclerosis in the coronary arteries (PLAC I).
Topics: Adult; Aged; Clinical Protocols; Coronary Artery Disease; Female; Humans; Male; Middle Aged; Pravastatin; Research Design | 1993 |
Evidence for a synergistic effect of calcium channel blockers with lipid-lowering therapy in retarding progression of coronary atherosclerosis in symptomatic patients with normal to moderately raised cholesterol levels. The REGRESS Study Group.
Topics: Aged; Anticholesteremic Agents; Calcium Channel Blockers; Cholesterol; Coronary Artery Disease; Drug Synergism; Drug Therapy, Combination; Humans; Middle Aged; Pravastatin | 1996 |
Effectiveness of probucol in preventing restenosis after percutaneous transluminal coronary angioplasty.
Topics: Angioplasty, Balloon, Coronary; Anticholesteremic Agents; Coronary Artery Disease; Female; Humans; Male; Middle Aged; Pravastatin; Probucol; Prospective Studies; Recurrence | 1996 |
The Asp9 Asn mutation in the lipoprotein lipase gene is associated with increased progression of coronary atherosclerosis. REGRESS Study Group, Interuniversity Cardiology Institute, Utrecht, The Netherlands. Regression Growth Evaluation Statin Study.
Topics: Amino Acid Sequence; Angioplasty, Balloon, Coronary; Cohort Studies; Coronary Angiography; Coronary Artery Bypass; Coronary Artery Disease; Disease Progression; Double-Blind Method; Genes; Heterozygote; Humans; Lipids; Lipoprotein Lipase; Lipoproteins; Middle Aged; Mutation; Pravastatin | 1996 |
Effect of pravastatin (10 mg/day) on progression of coronary atherosclerosis in patients with serum total cholesterol levels from 160 to 220 mg/dl and angiographically documented coronary artery disease. Coronary Artery Regression Study (CARS) Group.
Topics: Anticholesteremic Agents; Apolipoproteins B; Cholesterol; Cholesterol, LDL; Coronary Angiography; Coronary Artery Disease; Disease Progression; Female; Follow-Up Studies; Humans; Male; Middle Aged; Pravastatin; Prospective Studies; Time Factors | 1997 |
Tomorrow's world: atherosclerosis in the year 2000.
Topics: Anticholesteremic Agents; Coronary Artery Disease; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Male; Middle Aged; Pravastatin; Prospective Studies | 1997 |
Genetic variant showing a positive interaction with beta-blocking agents with a beneficial influence on lipoprotein lipase activity, HDL cholesterol, and triglyceride levels in coronary artery disease patients. The Ser447-stop substitution in the lipoprot
Topics: Adrenergic beta-Antagonists; Alleles; Cholesterol, HDL; Coronary Artery Disease; Enzyme Inhibitors; Gene Frequency; Genetic Variation; Genotype; Humans; Hydroxymethylglutaryl CoA Reductases; Lipoprotein Lipase; Male; Middle Aged; Mutation; Pravastatin; Triglycerides | 1997 |
Intravascular ultrasound analysis of reduction in progression of coronary narrowing by treatment with pravastatin.
Topics: Aged; Anticholesteremic Agents; Constriction, Pathologic; Coronary Artery Disease; Disease Progression; Humans; Male; Middle Aged; Pravastatin; Treatment Outcome; Ultrasonography, Interventional | 1997 |
Functional evaluation of lipid-lowering therapy by pravastatin in the Regression Growth Evaluation Statin Study (REGRESS)
Topics: Adult; Aged; Angina Pectoris; Anticholesteremic Agents; Coronary Angiography; Coronary Artery Disease; Double-Blind Method; Follow-Up Studies; Humans; Lipids; Middle Aged; Perfusion; Pravastatin | 1997 |
Modulation of lipoprotein(a) atherogenicity by high density lipoprotein cholesterol levels in middle-aged men with symptomatic coronary artery disease and normal to moderately elevated serum cholesterol. Regression Growth Evaluation Statin Study (REGRESS)
Topics: Anticholesteremic Agents; Cholesterol; Cholesterol, HDL; Coronary Angiography; Coronary Artery Disease; Disease Progression; Double-Blind Method; Humans; Hypercholesterolemia; Lipoprotein(a); Male; Middle Aged; Multivariate Analysis; Pravastatin; Prospective Studies; Reference Values | 1997 |
The role of a common variant of the cholesteryl ester transfer protein gene in the progression of coronary atherosclerosis. The Regression Growth Evaluation Statin Study Group.
Topics: Anticholesteremic Agents; Carrier Proteins; Cholesterol Ester Transfer Proteins; Cholesterol Esters; Cholesterol, HDL; Coronary Artery Disease; Disease Progression; Dose-Response Relationship, Drug; Glycoproteins; Humans; Hypercholesterolemia; Male; Middle Aged; Polymorphism, Genetic; Pravastatin; Prospective Studies | 1998 |
B-mode ultrasound assessment of pravastatin treatment effect on carotid and femoral artery walls and its correlations with coronary arteriographic findings: a report of the Regression Growth Evaluation Statin Study (REGRESS).
Topics: Anticholesteremic Agents; Carotid Arteries; Coronary Angiography; Coronary Artery Disease; Disease Progression; Femoral Artery; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Male; Middle Aged; Multicenter Studies as Topic; Pravastatin; Randomized Controlled Trials as Topic; Ultrasonography | 1998 |
Proposed synergistic effect of calcium channel blockers with lipid-lowering therapy in retarding progression of coronary atherosclerosis.
Topics: Anticholesteremic Agents; Calcium Channel Blockers; Coronary Artery Disease; Disease Progression; Drug Synergism; Drug Therapy, Combination; Follow-Up Studies; Humans; Pravastatin | 1998 |
Lipid management in patients at moderate risk for coronary heart disease: insights from the Air Force/Texas Coronary Atherosclerosis Prevention Study (AFCAPS/TexCAPS).
Topics: Age Factors; Aged; Anticholesteremic Agents; Coronary Artery Disease; Coronary Disease; Diabetes Mellitus, Type 2; Female; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypertension; Lovastatin; Male; Middle Aged; Military Personnel; Practice Guidelines as Topic; Pravastatin; Primary Prevention; Risk; Risk Factors; Sex Factors; Smoking; Texas; Treatment Outcome | 1999 |
Beneficial effects of pravastatin (+/-colestyramine/niacin) initiated immediately after a coronary event (the randomized Lipid-Coronary Artery Disease [L-CAD] Study).
Topics: Adult; Aged; Angina, Unstable; Angioplasty, Balloon, Coronary; Anticholesteremic Agents; Chemoprevention; Chi-Square Distribution; Cholesterol, LDL; Cholestyramine Resin; Confidence Intervals; Coronary Angiography; Coronary Artery Disease; Coronary Disease; Coronary Vessels; Drug Combinations; Female; Follow-Up Studies; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Male; Middle Aged; Myocardial Infarction; Niacin; Odds Ratio; Peripheral Vascular Diseases; Pravastatin; Regression Analysis; Statistics, Nonparametric; Stroke; Survival Rate; Treatment Outcome | 2000 |
Effects of pravastatin therapy on serum lipids and coronary reactivity are not associated with SREBP cleavage-activating protein polymorphism in healthy young men.
Topics: Adult; Analysis of Variance; Blood Flow Velocity; Coronary Artery Disease; Coronary Circulation; Electrocardiography; Follow-Up Studies; Genotype; Heart; Humans; Intracellular Signaling Peptides and Proteins; Lipids; Male; Membrane Proteins; Phenotype; Polymorphism, Genetic; Pravastatin | 2001 |
Effect of pravastatin on endothelial function in patients with coronary artery disease (cholesterol-independent effect of pravastatin).
Topics: Acetylcholine; Anticholesteremic Agents; Cholesterol; Coronary Artery Disease; Endothelium, Vascular; Forearm; Humans; Middle Aged; Nitric Oxide; Nitric Oxide Synthase; omega-N-Methylarginine; Pravastatin; Vasodilation; Vasodilator Agents | 2001 |
The effects of hydroxy-methyl-glutaryl co-enzyme A reductase inhibitors on platelet thrombus formation.
Topics: Aged; Analysis of Variance; Blood Platelets; Chi-Square Distribution; Coronary Artery Disease; Coronary Thrombosis; Dose-Response Relationship, Drug; Double-Blind Method; Drug Administration Schedule; Female; Follow-Up Studies; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Male; Middle Aged; Pravastatin; Probability; Reference Values; Simvastatin; Treatment Outcome | 2002 |
Angiographic intervention trial using HMG CoA reductase inhibitor to evaluate retardation of obstructive multiple atheroma in West Japan (ATHEROMA study): rationale, design and baseline.
Topics: Adult; Aged; Cholesterol; Coronary Angiography; Coronary Artery Disease; Coronary Vessels; Female; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Japan; Lipoproteins; Male; Middle Aged; Pravastatin; Prospective Studies; Triglycerides | 2002 |
Relations of lipoprotein subclass levels and low-density lipoprotein size to progression of coronary artery disease in the Pravastatin Limitation of Atherosclerosis in the Coronary Arteries (PLAC-I) trial.
Topics: Anticholesteremic Agents; Cholesterol; Coronary Angiography; Coronary Artery Disease; Coronary Vessels; Disease Progression; Female; Humans; Lipoproteins; Lipoproteins, LDL; Male; Middle Aged; Particle Size; Pravastatin; Treatment Outcome | 2002 |
Regression of coronary atherosclerosis by combined LDL-apheresis and lipid-lowering drug therapy in patients with familial hypercholesterolemia: a multicenter study. The LARS Investigators.
Topics: Adult; Blood Component Removal; Cholesterol, LDL; Combined Modality Therapy; Coronary Angiography; Coronary Artery Disease; Female; Humans; Hyperlipoproteinemia Type II; Lipids; Male; Middle Aged; Pravastatin; Probucol | 1992 |
76 other study(ies) available for pravastatin and Arteriosclerosis, Coronary
| Article | Year |
|---|---|
Persistent psychological distress and mortality in patients with stable coronary artery disease.
Topics: Adult; Aged; Angina, Unstable; Australia; Coronary Artery Disease; Female; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Kaplan-Meier Estimate; Logistic Models; Male; Middle Aged; Myocardial Infarction; New Zealand; Odds Ratio; Pravastatin; Prognosis; Proportional Hazards Models; Risk Assessment; Risk Factors; Severity of Illness Index; Stress, Psychological; Surveys and Questionnaires; Time Factors | 2017 |
Atorvastatin-Induced Dermatomyositis: Resolution With Change in Statin?
Topics: Antibodies, Antinuclear; Atorvastatin; Autoantibodies; Autoimmunity; Biopsy; Coronary Artery Disease; Dermatomyositis; Diagnosis, Differential; Drug Substitution; Female; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Middle Aged; Muscle Weakness; Pravastatin; Serologic Tests; Skin; Treatment Outcome | 2018 |
Pravastatin improves endothelial function in arteries used in coronary bypass grafting.
Topics: 15-Hydroxy-11 alpha,9 alpha-(epoxymethano)prosta-5,13-dienoic Acid; Acetylcholine; Aged; Coronary Artery Bypass; Coronary Artery Disease; Endothelium, Vascular; Female; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Male; Mammary Arteries; Nitroprusside; Phenylephrine; Postoperative Period; Pravastatin; Radial Artery; Vasoconstriction; Vasoconstrictor Agents; Vasodilator Agents | 2013 |
Impact of lysophosphatidylcholine on survival and function of UEA-1(+)acLDL (+) endothelial progenitor cells in patients with coronary artery disease.
Topics: Apoptosis; Cell Adhesion; Cell Movement; Cells, Cultured; Coronary Artery Disease; Endothelial Progenitor Cells; Female; Humans; Leukocytes, Mononuclear; Lipoproteins, LDL; Lysophosphatidylcholines; Male; Middle Aged; Nitric Oxide Synthase Type III; Phosphorylation; Plant Lectins; Pravastatin; Proto-Oncogene Proteins c-akt | 2015 |
Statins and prevention of stent-related late adverse events.
Topics: Coronary Artery Disease; Coronary Vessels; Drug-Eluting Stents; Female; Fluorobenzenes; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Male; Neointima; Percutaneous Coronary Intervention; Pravastatin; Pyrimidines; Rosuvastatin Calcium; Sulfonamides | 2014 |
The anti-inflammatory and antioxidant effects of pravastatin and nebivolol in rat aorta.
Topics: Adrenergic beta-1 Receptor Antagonists; Animals; Aorta; Ceruloplasmin; Cholesterol; Coronary Artery Disease; Disease Models, Animal; Female; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Inflammation; Nebivolol; NG-Nitroarginine Methyl Ester; Pravastatin; Rats; Rats, Wistar; Triglycerides; Uric Acid | 2014 |
The relation between extent of coronary artery disease measured by quantitative coronary angiography and changes in lipid profile: insights from trials of atherosclerosis regression.
Topics: Anticholesteremic Agents; Atorvastatin; Cholesterol, HDL; Cholesterol, LDL; Coronary Angiography; Coronary Artery Disease; Coronary Stenosis; Coronary Vessels; Disease Progression; Female; Fluorobenzenes; Follow-Up Studies; Heptanoic Acids; Humans; Male; Middle Aged; Pravastatin; Pyrimidines; Pyrroles; Randomized Controlled Trials as Topic; Risk Factors; Rosuvastatin Calcium; Sulfonamides; Treatment Outcome; Ultrasonography, Interventional | 2008 |
Decreased plasma and cardiac matrix metalloproteinase activities in patients with coronary artery disease and treated with pravastatin.
Topics: Aged; Coronary Angiography; Coronary Artery Bypass; Coronary Artery Disease; Dinoprost; Electrophoresis, Polyacrylamide Gel; Female; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Male; Matrix Metalloproteinase 2; Matrix Metalloproteinase 9; Matrix Metalloproteinases; Middle Aged; Myocardium; Oxidative Stress; Pericardial Effusion; Pravastatin | 2008 |
CETP genotype predicts increased mortality in statin-treated men with proven cardiovascular disease: an adverse pharmacogenetic interaction.
Topics: Alleles; Anticholesteremic Agents; Cholesterol Ester Transfer Proteins; Cholesterol, HDL; Coronary Artery Disease; Genotype; Humans; Male; Pharmacogenetics; Polymorphism, Genetic; Pravastatin; Predictive Value of Tests; Quinolines; Randomized Controlled Trials as Topic | 2008 |
The cornucopia of "pleiotropic" actions of statins: myogenesis as a new mechanism for statin-induced benefits?
Topics: Animals; Bone Marrow Cells; Cell Movement; Cell Proliferation; Coronary Artery Disease; Coronary Circulation; Hemodynamics; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Muscle Contraction; Muscle Development; Myocytes, Cardiac; Pravastatin; Regeneration; Stem Cells | 2009 |
The impact of pravastatin therapy on long-term outcome in patients with metabolic syndrome undergoing complete coronary revascularization.
Topics: Aged; Asian People; Coronary Artery Disease; Female; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Japan; Kaplan-Meier Estimate; Male; Metabolic Syndrome; Middle Aged; Myocardial Revascularization; Pravastatin; Proportional Hazards Models; Risk Factors; Time Factors; Treatment Outcome | 2009 |
Long-term efficacy of pravastatin therapy in diabetic patients undergoing complete coronary revascularization.
Topics: Coronary Artery Disease; Diabetes Complications; Diabetes Mellitus; Female; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Male; Middle Aged; Myocardial Revascularization; Pravastatin; Risk Factors; Survival Rate; Treatment Outcome | 2010 |
Mannose binding lectin 2 haplotypes do not affect the progression of coronary atherosclerosis in men with proven coronary artery disease treated with pravastatin.
Topics: Coronary Angiography; Coronary Artery Disease; Disease Progression; Genotype; Haplotypes; Humans; Male; Mannose-Binding Lectin; Middle Aged; Polymorphism, Genetic; Pravastatin | 2011 |
Development of a model for prediction of coronary atherosclerotic regression: evaluation of high-density lipoprotein cholesterol level and peripheral blood monocyte count.
Topics: Aged; Angioplasty, Balloon, Coronary; Biomarkers; Cholesterol, HDL; Coronary Artery Disease; Female; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Japan; Leukocyte Count; Male; Middle Aged; Monocytes; Multivariate Analysis; Pravastatin; Predictive Value of Tests; Prospective Studies; Regression Analysis; Risk Assessment; Risk Factors; Time Factors; Treatment Outcome; Ultrasonography, Interventional | 2012 |
HMG CoA reduction in patients with average cholesterol concentrations.
Topics: Cholesterol; Coronary Artery Disease; Humans; Hydroxymethylglutaryl CoA Reductases; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Myocardial Infarction; Pravastatin; Randomized Controlled Trials as Topic; Recurrence | 2011 |
HMG-CoA reductase inhibitor (Statin) therapy and coronary atherosclerosis in Japanese subjects: role of high-density lipoprotein cholesterol.
Topics: Aged; Area Under Curve; Cholesterol, HDL; Cholesterol, LDL; Coronary Artery Disease; Disease Progression; Female; Follow-Up Studies; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Japan; Male; Middle Aged; Plaque, Atherosclerotic; Pravastatin; Prospective Studies; ROC Curve; Sensitivity and Specificity; Treatment Outcome | 2011 |
Aggregate-data estimation of an individual patient data linear random effects meta-analysis with a patient covariate-treatment interaction term.
Topics: Algorithms; Analysis of Variance; Bayes Theorem; Biostatistics; Cholesterol; Coronary Artery Disease; Data Interpretation, Statistical; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Likelihood Functions; Linear Models; Male; Meta-Analysis as Topic; Pravastatin; Randomized Controlled Trials as Topic; Software; Treatment Outcome | 2013 |
Adherence to preferable behavior for lipid control by high-risk dyslipidemic Japanese patients under pravastatin treatment: the APPROACH-J study.
Topics: Aged; Asian People; Awareness; Coronary Artery Disease; Diet; Dyslipidemias; Exercise; Female; Follow-Up Studies; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Lipids; Male; Patient Compliance; Pravastatin; Primary Prevention; Prognosis; Surveys and Questionnaires | 2012 |
Factors affecting low-density lipoprotein and high-density lipoprotein cholesterol response to pravastatin in the West Of Scotland Coronary Prevention Study (WOSCOPS).
Topics: Alcohol Drinking; Anticholesteremic Agents; Body Mass Index; Cholesterol, HDL; Cholesterol, LDL; Cohort Studies; Coronary Artery Disease; Humans; Lipoproteins; Male; Middle Aged; Patient Compliance; Pravastatin; Randomized Controlled Trials as Topic; Risk Factors; Scotland; Treatment Outcome; Triglycerides | 2002 |
Gastrointestinal cancer and the long-term use of pravastatin in the elderly.
Topics: Aged; Aged, 80 and over; Anticholesteremic Agents; Confounding Factors, Epidemiologic; Coronary Artery Disease; Female; Gastrointestinal Neoplasms; Humans; Incidence; Male; Pravastatin; Randomized Controlled Trials as Topic | 2003 |
Prospective serial evaluation of myocardial perfusion and lipids during the first six months of pravastatin therapy: coronary artery disease regression single photon emission computed tomography monitoring trial.
Topics: Aged; Coronary Artery Disease; Coronary Circulation; Coronary Vessels; Female; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hyperlipidemias; Lipid Metabolism; Lipids; Male; Middle Aged; Pilot Projects; Pravastatin; Prospective Studies; Tomography, Emission-Computed, Single-Photon | 2003 |
Effect of pravastatin on coronary plaque volume.
Topics: Adult; Aged; Aged, 80 and over; Cholesterol, HDL; Cholesterol, LDL; Coronary Artery Disease; Coronary Vessels; Female; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Imaging, Three-Dimensional; Male; Middle Aged; Pravastatin; Treatment Outcome; Ultrasonography, Interventional | 2003 |
Current perspectives on statins.
Topics: Adult; Aged; Anticholesteremic Agents; Cholesterol; Cholestyramine Resin; Coronary Artery Disease; Female; Humans; India; Lovastatin; Male; Middle Aged; Pravastatin; Randomized Controlled Trials as Topic; Simvastatin | 2003 |
Effect of statins on the progression of bioprosthetic aortic valve degeneration.
Topics: Aged; Aortic Valve; Aortic Valve Insufficiency; Aortic Valve Stenosis; Atorvastatin; Bioprosthesis; Coronary Artery Bypass; Coronary Artery Disease; Female; Heart Valve Prosthesis; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Male; Pravastatin; Prosthesis Failure; Pyrroles; Retrospective Studies; Simvastatin; Treatment Outcome; Ultrasonography | 2003 |
Aggressive lipid-lowering regimen halts CHD progression.
Topics: Anticholesteremic Agents; Atorvastatin; Cholesterol, LDL; Coronary Artery Disease; Drug Administration Schedule; Heptanoic Acids; Humans; Pravastatin; Pyrroles; Randomized Controlled Trials as Topic | 2004 |
[First comparison of 2 statins shows: only radical LDL lowering stops coronary atherosclerosis].
Topics: Anticholesteremic Agents; Atorvastatin; Cholesterol, LDL; Clinical Trials as Topic; Coronary Artery Disease; Follow-Up Studies; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Pravastatin; Pyrroles; Time Factors; Ultrasonography, Interventional | 2003 |
High-intensity statin treatment for coronary heart disease.
Topics: Anticholesteremic Agents; Atorvastatin; Cholesterol, LDL; Coronary Artery Disease; Coronary Vessels; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Patient Dropouts; Pravastatin; Pyrroles; Risk Factors; Ultrasonography, Interventional | 2004 |
The cholesteryl ester transfer protein (CETP) TaqIB polymorphism in the cholesterol and recurrent events study: no interaction with the response to pravastatin therapy and no effects on cardiovascular outcome: a prospective analysis of the CETP TaqIB poly
Topics: Adult; Aged; Anticholesteremic Agents; Carrier Proteins; Cholesterol Ester Transfer Proteins; Coronary Artery Disease; Female; Glycoproteins; Humans; Male; Middle Aged; Polymorphism, Genetic; Pravastatin; Prospective Studies; Recurrence; Site-Specific DNA-Methyltransferase (Adenine-Specific); Time Factors; Treatment Outcome | 2004 |
C-reactive protein is not only an inflammatory marker but also a direct cause of cardiovascular diseases.
Topics: Acute-Phase Reaction; Aspirin; Atorvastatin; Biomarkers; C-Reactive Protein; Cardiovascular Diseases; Clinical Trials as Topic; Coronary Artery Disease; Heptanoic Acids; Humans; Incidence; Inflammation; Interleukin-6; Lovastatin; Pravastatin; Predictive Value of Tests; Pyrroles; Risk Factors; Simvastatin | 2004 |
[Lower, lower, lower. The LDL goal value of 200 mg/dl is still much too high].
Topics: Atorvastatin; Cholesterol, LDL; Clinical Trials as Topic; Coronary Artery Disease; Dose-Response Relationship, Drug; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Myocardial Infarction; Pravastatin; Pyrroles; Reference Values; Risk; Survival Analysis; Survival Rate | 2004 |
[Results of randomized study: intensive lipid lowering treatment stops coronary atherosclerosis].
Topics: Anticholesteremic Agents; Atorvastatin; C-Reactive Protein; Cholesterol, LDL; Coronary Artery Disease; Dose-Response Relationship, Drug; Female; Heptanoic Acids; Humans; Hypercholesterolemia; Male; Middle Aged; Pravastatin; Pyrroles; Randomized Controlled Trials as Topic; Treatment Outcome; Ultrasonography, Interventional | 2004 |
Reversal of atherosclerosis with aggressive lipid lowering.
Topics: Anticholesteremic Agents; Atorvastatin; Biomarkers; C-Reactive Protein; Cholesterol, LDL; Coronary Artery Disease; Heptanoic Acids; Humans; Hyperlipidemias; Pravastatin; Pyrroles; Randomized Controlled Trials as Topic; Treatment Outcome | 2005 |
Multiple antiplatelet effects of clopidogrel are not modulated by statin type in patients undergoing percutaneous coronary intervention.
Topics: Adult; Aged; Angioplasty, Balloon, Coronary; Atorvastatin; Blood Platelets; Clopidogrel; Coronary Artery Disease; Drug Evaluation; Drug Interactions; Drug Therapy, Combination; Fatty Acids, Monounsaturated; Female; Fluvastatin; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Indoles; Male; Middle Aged; Platelet Aggregation; Platelet Aggregation Inhibitors; Pravastatin; Pyrroles; Simvastatin; Ticlopidine | 2004 |
Electrocardiographic events and cholesterol reduction with pravastatin in patients with hypercholesterolemia: the Hokuriku Lipid Coronary Heart Disease Study-Pravastatin Atherosclerosis Trial.
Topics: Aged; Anticholesteremic Agents; Cholesterol; Cholesterol, LDL; Coronary Artery Disease; Electrocardiography; Female; Humans; Hypercholesterolemia; Male; Middle Aged; Pravastatin; Risk | 2005 |
Cholesteryl ester transfer protein TaqIB polymorphism in the cholesterol and recurrent events study.
Topics: Anticholesteremic Agents; Carrier Proteins; Cholesterol Ester Transfer Proteins; Cholesterol, HDL; Cholesterol, LDL; Coronary Artery Disease; Enzyme-Linked Immunosorbent Assay; Female; Follow-Up Studies; Genotype; Glycoproteins; Humans; Male; Polymorphism, Genetic; Pravastatin; Prospective Studies; Randomized Controlled Trials as Topic; Site-Specific DNA-Methyltransferase (Adenine-Specific) | 2005 |
[Protective effects of pravastatin against atherosclerosis in children with familial hypercholesterolemia].
Topics: Child; Coronary Artery Disease; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hyperlipoproteinemia Type II; Pravastatin; Randomized Controlled Trials as Topic | 2005 |
Treatment strategies in endothelial dysfunction: physical exercise versus pharmacological therapy.
Topics: Coronary Artery Disease; Coronary Circulation; Endothelium, Vascular; Exercise; Exercise Tolerance; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Oxygen Consumption; Physical Endurance; Pravastatin; Regional Blood Flow; Vascular Resistance; Vasodilation | 2005 |
REVERSAL and PROVE-IT: are clinically oriented trials really better than "pure" scientific studies?
Topics: Atorvastatin; Coronary Artery Disease; Data Interpretation, Statistical; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Outcome Assessment, Health Care; Pravastatin; Pyrroles; Randomized Controlled Trials as Topic | 2005 |
Impact of the pravastatin or atorvastatin evaluation and infection therapy-thrombolysis in myocardial infarction 22/Reversal of Atherosclerosis with Aggressive Lipid Lowering trials on trends in intensive versus moderate statin therapy in Ontario, Canada.
Topics: Aged; Atorvastatin; Coronary Artery Disease; Drug Utilization; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Infections; Myocardial Infarction; Pravastatin; Pyrroles; Randomized Controlled Trials as Topic; Retrospective Studies; Thrombolytic Therapy | 2005 |
Cost-effectiveness of pravastatin for primary prevention of coronary artery disease in Japan.
Topics: Adult; Age Factors; Aged; Anticholesteremic Agents; Biomarkers; Coronary Artery Disease; Cost-Benefit Analysis; Female; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Japan; Male; Middle Aged; Pravastatin; Primary Prevention; Quality-Adjusted Life Years; Risk Factors; Sensitivity and Specificity; Treatment Outcome; Triglycerides | 2005 |
Effect of atorvastatin (80 mg/day) versus pravastatin (40 mg/day) on arterial remodeling at coronary branch points (from the REVERSAL study).
Topics: Adult; Aged; Anticholesteremic Agents; Atorvastatin; Cholesterol, LDL; Coronary Angiography; Coronary Artery Disease; Coronary Vessels; Dose-Response Relationship, Drug; Female; Follow-Up Studies; Heptanoic Acids; Humans; Male; Middle Aged; Pravastatin; Pyrroles; Treatment Outcome; Ultrasonography, Interventional | 2005 |
Low high-density lipoprotein cholesterol and cardiovascular disease: risk reduction with statin therapy.
Topics: Atorvastatin; Cardiovascular Diseases; Cholesterol, HDL; Cholesterol, LDL; Coronary Artery Disease; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Lovastatin; Particle Size; Polymorphism, Genetic; Pravastatin; Pyrroles; Risk Factors; Simvastatin | 2006 |
[Statin therapy: cost-effectiveness and evaluation of evidence as criterium for improving expenditure within the National Health Program].
Topics: Adrenergic beta-Antagonists; Angiotensin-Converting Enzyme Inhibitors; Anti-Inflammatory Agents, Non-Steroidal; Anticholesteremic Agents; Coronary Artery Disease; Cost-Benefit Analysis; Drug Costs; Drug Therapy, Combination; Evaluation Studies as Topic; Female; Humans; Italy; Middle Aged; National Health Programs; Obesity; Pravastatin; Thyroiditis, Autoimmune | 2006 |
Plasma cholesteryl ester transfer protein concentrations predict cardiovascular events in patients with coronary artery disease treated with pravastatin.
Topics: Adult; Aged; Analysis of Variance; Anticholesteremic Agents; Biomarkers; Cardiovascular Diseases; Carrier Proteins; Cholesterol Ester Transfer Proteins; Cholesterol, LDL; Coronary Artery Disease; Female; Genetic Markers; Genotype; Glycoproteins; Humans; Hypercholesterolemia; Male; Middle Aged; Polymorphism, Restriction Fragment Length; Pravastatin; Prospective Studies | 2006 |
The effect of 6 months of treatment with pravastatin on serum adiponection concentrations in Japanese patients with coronary artery disease and hypercholesterolemia: a pilot study.
Topics: Adiponectin; Aged; Cholesterol; Coronary Artery Disease; Endpoint Determination; Enzyme-Linked Immunosorbent Assay; Female; Glycated Hemoglobin; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Japan; Male; Middle Aged; Pilot Projects; Pravastatin; Triglycerides | 2006 |
[Medical treatment in peripheral arterial disease: a professional practice study in 262 patients].
Topics: Aged; Aged, 80 and over; Angiotensin-Converting Enzyme Inhibitors; Coronary Artery Disease; Drug Therapy, Combination; Female; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Male; Medical Records; Middle Aged; Peripheral Vascular Diseases; Platelet Aggregation Inhibitors; Practice Patterns, Physicians'; Pravastatin; Retrospective Studies; Stroke | 2007 |
A case of vasospastic angina showing resolution of coronary vasospasm in acetylcholine provocation test corresponding to regression of coronary atherosclerosis.
Topics: Acetylcholine; Angina Pectoris; Angina Pectoris, Variant; Anticholesteremic Agents; Cholinergic Agents; Coronary Artery Disease; Coronary Vasospasm; Dihydropyridines; Humans; Hypercholesterolemia; Male; Middle Aged; Pravastatin; Ultrasonography; Vasodilator Agents | 2008 |
Lowering LDL-C for optimal protection in high-risk patients.
Topics: Anticholesteremic Agents; Atorvastatin; Cholesterol, LDL; Coronary Artery Disease; Diabetes Mellitus; Guideline Adherence; Heptanoic Acids; Humans; Hypercholesterolemia; Practice Guidelines as Topic; Pravastatin; Pyrroles; Risk Assessment | 2008 |
Direct effect of statins on homocysteine-induced endothelial adhesiveness: potential impact to human atherosclerosis.
Topics: Aged; Anticholesteremic Agents; Case-Control Studies; Cell Adhesion; Cell Adhesion Molecules; Coronary Artery Disease; Endothelial Cells; Endothelium, Vascular; Female; Homocysteine; Humans; Male; Middle Aged; Pravastatin; Simvastatin | 2008 |
[The significance of improvement of the lipid profile on progression and regression of the coronary atherosclerosis--a quantitative analysis using coronary angiography].
Topics: Coronary Angiography; Coronary Artery Disease; Female; Humans; Lipids; Male; Middle Aged; Pravastatin | 1994 |
[Reduction of cardiovascular events with pravastatin. A pooled analysis of clinical events within the scope of the Pravastatin Atherosclerosis Intervention Program].
Topics: Adult; Aged; Anticholesteremic Agents; Coronary Artery Disease; Double-Blind Method; Female; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Male; Middle Aged; Myocardial Infarction; Pravastatin; Randomized Controlled Trials as Topic; Survival Rate; Treatment Outcome | 1996 |
The influence of angiographic endpoints on the outcome of lipid intervention studies. A proposal for standardization. REGRESS study group.
Topics: Angioplasty, Balloon, Coronary; Anticholesteremic Agents; Cholesterol; Constriction, Pathologic; Coronary Angiography; Coronary Artery Bypass; Coronary Artery Disease; Humans; Multicenter Studies as Topic; Pravastatin; Randomized Controlled Trials as Topic; Treatment Outcome | 1996 |
The beneficial effects of HMG-coenzyme A reductase inhibitor in the primary and secondary prevention of atherosclerosis in the coronaries.
Topics: Anticholesteremic Agents; Coronary Artery Disease; Female; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Lovastatin; Male; Middle Aged; Pravastatin | 1996 |
Cost-effectiveness of pravastatin in secondary prevention of coronary artery disease.
Topics: Anticholesteremic Agents; Arteriosclerosis; Carotid Artery Diseases; Chemoprevention; Cholesterol, LDL; Coronary Artery Disease; Coronary Disease; Cost-Benefit Analysis; Costs and Cost Analysis; Decision Support Techniques; Hospitalization; Humans; Life Expectancy; Life Tables; Male; Markov Chains; Middle Aged; Myocardial Infarction; Placebos; Pravastatin; Risk Factors; Treatment Outcome; Value of Life | 1996 |
Atherosclerosis and restenosis: reflections on the Lovastatin Restenosis Trial and Scandinavian Simvastatin Survival Study.
Topics: Angioplasty, Balloon, Coronary; Anticholesteremic Agents; Coronary Artery Disease; Death, Sudden, Cardiac; Humans; Lovastatin; Myocardial Infarction; Pravastatin; Randomized Controlled Trials as Topic; Recurrence; Scandinavian and Nordic Countries; Simvastatin; Survival Analysis | 1996 |
Pravastatin prevents the progression of accelerated coronary artery disease after heart transplantation in a rabbit model.
Topics: Animals; Anticholesteremic Agents; Coronary Artery Disease; Graft Rejection; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Lipids; Liver Transplantation; Male; Pravastatin; Rabbits | 1996 |
[A break-through in infarct prevention. WOS (West-of-Scotland)-study confirms effectiveness of early intervention using Pravastin].
Topics: Anticholesteremic Agents; Coronary Artery Disease; Humans; Myocardial Infarction; Pravastatin | 1996 |
In search of perverse polymorphisms.
Topics: Anticholesteremic Agents; Blood Coagulation; Carrier Proteins; Cholesterol Ester Transfer Proteins; Coronary Artery Disease; Factor VII; Glycoproteins; Humans; Myocardial Infarction; Polymorphism, Genetic; Pravastatin | 1998 |
On the statistical modelling of coronary arteriographic data: dynamics of coronary atherosclerosis related to systemic and focal parameters. REGRESS Study Group. Regression Growth Evaluation Statin Study.
Topics: Angioplasty, Balloon, Coronary; Anticholesteremic Agents; Coronary Angiography; Coronary Artery Bypass; Coronary Artery Disease; Humans; Likelihood Functions; Models, Biological; Pravastatin; Regression Analysis; Statistics as Topic | 1997 |
Pravastatin has cholesterol-lowering independent effects on the artery wall of atherosclerotic monkeys.
Topics: Acetylcholine; Animals; Anticholesteremic Agents; Arteriosclerosis; Confounding Factors, Epidemiologic; Coronary Artery Disease; Coronary Vessels; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Lipids; Macaca fascicularis; Pravastatin; Time Factors; Vasoconstriction; Vasodilation | 1998 |
Polymorphism of the cholesteryl ester transfer protein gene.
Topics: Carrier Proteins; Cholesterol Ester Transfer Proteins; Coronary Artery Disease; Disease Progression; Glycoproteins; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Male; Middle Aged; Polymorphism, Genetic; Pravastatin | 1998 |
Polymorphism of the cholesteryl ester transfer protein gene.
Topics: Alcohol Drinking; Carrier Proteins; Cholesterol Ester Transfer Proteins; Cholesterol, HDL; Cholesterol, LDL; Coronary Artery Disease; Diet; Disease Progression; Genotype; Glycoproteins; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Pravastatin | 1998 |
Survival and cardiovascular pathology of heterozygous Watanabe heritable hyperlipidaemic rabbits treated with pravastatin and probucol on a low-cholesterol (0.03%)-enriched diet.
Topics: Animals; Aorta; Cholesterol; Cholesterol, Dietary; Coronary Artery Disease; Drug Therapy, Combination; Female; Hyperlipidemias; Immunohistochemistry; Liver; Male; Pravastatin; Probucol; Rabbits; Survival Rate; Treatment Outcome | 1998 |
Effect of the stromelysin-1 promoter on efficacy of pravastatin in coronary atherosclerosis and restenosis.
Topics: Anticholesteremic Agents; Cholesterol; Coronary Artery Disease; Disease-Free Survival; Genotype; Humans; Male; Matrix Metalloproteinase 3; Multicenter Studies as Topic; Polymorphism, Genetic; Pravastatin; Promoter Regions, Genetic; Randomized Controlled Trials as Topic; Recurrence; Treatment Outcome | 1999 |
Non lipid, dose-dependent effects of pravastatin treatment on hemostatic system and inflammatory response.
Topics: Blood Coagulation Factors; Blood Glucose; Case-Control Studies; Cholesterol; Coronary Artery Disease; Cross-Sectional Studies; Dose-Response Relationship, Drug; Female; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Inflammation; Male; Middle Aged; Myocardial Infarction; Pravastatin; Risk Factors | 2000 |
Update in women's health.
Topics: Anticholesteremic Agents; Breast Neoplasms; Clinical Trials as Topic; Coronary Artery Disease; Female; Humans; Lovastatin; Pravastatin; Women's Health | 2000 |
High-sensitivity C-reactive protein and atherosclerosis: from theory to therapy.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Anticholesteremic Agents; Aspirin; Biomarkers; C-Reactive Protein; Coronary Artery Disease; Coronary Disease; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Pravastatin; Risk Factors | 2000 |
HMG-CoA reductase inhibitors prevent migration of human coronary smooth muscle cells through suppression of increase in oxidative stress.
Topics: Antioxidants; Cell Movement; Cells, Cultured; Coronary Artery Disease; Coronary Vessels; Fatty Acids, Monounsaturated; Fluvastatin; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Indoles; Isoenzymes; Lysophosphatidylcholines; Mevalonic Acid; Muscle, Smooth, Vascular; Oligonucleotides, Antisense; Oxidative Stress; Phospholipase D; Pravastatin; Protein Kinase C; Protein Kinase C beta; Protein Kinase C-alpha; Protein-Tyrosine Kinases; Simvastatin | 2001 |
Remarkably high prevalence of small dense low-density lipoprotein in Japanese men with coronary artery disease, irrespective of the presence of diabetes.
Topics: Aged; Apolipoprotein A-I; Apolipoproteins B; Blood Glucose; Body Mass Index; Coronary Artery Disease; Diabetes Mellitus, Type 2; Glycated Hemoglobin; Humans; Hypolipidemic Agents; Japan; Lipoprotein(a); Lipoproteins, HDL; Lipoproteins, LDL; Male; Middle Aged; Pravastatin; Prevalence; Simvastatin; Triglycerides | 2002 |
The use over time of statins in coronary patients in an Italian tertiary referral center.
Topics: Aged; Anticholesteremic Agents; Atorvastatin; C-Reactive Protein; Cholesterol, LDL; Coronary Artery Disease; Drug Utilization Review; Fatty Acids, Monounsaturated; Female; Fluvastatin; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Indoles; Italy; Male; Middle Aged; Practice Patterns, Physicians'; Pravastatin; Pyrroles; Retrospective Studies; Risk Factors; Simvastatin | 2001 |
Statins and mortality.
Topics: Cholesterol; Coronary Artery Disease; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Pravastatin; Survival Analysis; Treatment Outcome | 2002 |
Early benefits of pravastatin to experimentally induced atherosclerosis.
Topics: Acetylcholine; Animals; Anticholesteremic Agents; Aorta, Thoracic; Cholesterol; Coronary Artery Disease; Diet, Atherogenic; Endothelium, Vascular; Immunohistochemistry; Male; Muscle, Smooth, Vascular; Nitroprusside; Pravastatin; Rabbits; Time Factors; Tunica Intima; Tunica Media; Vasodilation; Vasodilator Agents | 2002 |
Withdrawal of statins increases event rates in patients with acute coronary syndromes.
Topics: Acute Disease; Cholesterol; Clinical Trials as Topic; Comorbidity; Coronary Artery Disease; Dose-Response Relationship, Drug; Female; Follow-Up Studies; Heparin; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Incidence; Lovastatin; Male; Middle Aged; Myocardial Infarction; Odds Ratio; Platelet Aggregation Inhibitors; Pravastatin; Proportional Hazards Models; Risk Factors; Simvastatin; Substance Withdrawal Syndrome; Survival Rate; Treatment Outcome; Troponin; United States | 2002 |
Lipid-lowering drug use and cardiovascular events after myocardial infarction.
Topics: Cholesterol; Clofibrate; Cohort Studies; Coronary Artery Disease; Coronary Disease; Female; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hyperlipidemias; Hypolipidemic Agents; Male; Middle Aged; Myocardial Infarction; Niacin; Pravastatin; Risk Factors; Simvastatin; Stroke; Treatment Outcome | 2002 |
The role of oxidized lipoproteins in the pathogenesis of atherosclerosis.
Topics: Animals; Apolipoproteins B; Cholesterol Esters; Cholestyramine Resin; Coronary Artery Disease; Lipoproteins; Lipoproteins, HDL; Lipoproteins, LDL; Macrophages; Mice; Oxidation-Reduction; Pravastatin; Probucol; Rabbits; Receptors, LDL; RNA, Messenger | 1992 |
Preventive effect of pravastatin sodium, a potent inhibitor of 3-hydroxy-3-methylglutaryl coenzyme A reductase, on coronary atherosclerosis and xanthoma in WHHL rabbits.
Topics: Animals; Cholesterol; Coronary Artery Disease; Coronary Vessels; Heptanoic Acids; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Lipids; Naphthalenes; Phospholipids; Pravastatin; Rabbits; Xanthomatosis | 1988 |